

Electronic Supporting Information

Nickel(II)-catalyzed asymmetric thio-Claisen rearrangement of α -diazo pyrazoleamides with thioindoles

Wei Yang, Xiaobin Lin, Yongyan Zhang, Weidi Cao, Xiaohua Liu* and Xiaoming Feng*

[†]*Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, China.*

E-mail: liuxh@scu.edu.cn; xmfeng@scu.edu.cn

Table of Contents

| | |
|--|-----|
| 1 General information | 2 |
| 2 General procedure for the synthesis of substrates and ligands | 2 |
| 3 Characterization of α -diazo pyrazoleamides | 4 |
| 4 Characterization of 2-(alkylthio)-1 <i>H</i> -indole..... | 6 |
| 5 Characterization of chiral <i>N,N'</i> -dioxides..... | 11 |
| 6 Typical experimental procedure for the asymmetric [3,3]-rearrangement | 14 |
| 7 The list of substrates scope | 24 |
| 8 Procedure for the transformation of product 3aa and 4aa | 25 |
| 9 Control experiments and mechanistic studies..... | 28 |
| 10 X-ray crystal structure..... | 33 |
| 11 Spectral characterization data and HPLC conditions for the products | 35 |
| 12 References..... | 72 |
| 13 ^1H , ^{13}C NMR spectra of the substrates and products | 74 |
| 14 Copies of CD spectra in CH_2Cl_2 | 157 |

1 General information


¹H NMR spectra were recorded at 400 MHz. The chemical shifts were recorded in ppm relative to tetramethylsilane and with the solvent resonance as the internal standard. Data were reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiple, br = broad), coupling constants (Hz), integration. ¹³C NMR data were collected at 100 MHz with complete proton decoupling. Melting points (Mp) were determined using OptiMelt automated melting point system. Enantiomeric excesses (ee) were determined by chiral HPLC analysis on Daicel chiralcel IA, chiralcel IC, chiralcel ID, chiralcel IE, chiralcel IF and chiralcel Phenomenex Lux 5u Cellulose-2 columns in comparison with the authentic racemates. Optical rotations were reported as follows: [α]^T_D (c: g/100 mL, in solvent). ESI-HRMS spectra were recorded on a commercial apparatus and methanol and water were used to dissolve the sample. THF was distilled from sodium benzophenone ketyl. CH₂Cl₂, CHCl₃, ClCH₂CH₂Cl, Cl₂CHCHCl₂, Cl₂CHCH₂Cl were distilled over CaH₂. Unless noted, other commercial reagents were used without further purification.

2 General procedure for the synthesis of substrates and ligands

2.1 General procedure for the synthesis of α -diazo pyrazoleamides

α -Diazo pyrazoleamides were synthesized according to our previous work¹. Olefinic acid was synthesized according to the literature².


(Z)-4-phenylbut-3-enoic acid has been prepared according the following route:




To a solution of NiCl₂(PPh₃)₂ (196 mg, 0.3 mmol, 0.02 equiv) in dry THF (15 mL) under nitrogen at 0 °C, 2,3-dihydrofuran (1.14 mL, 15 mmol, 1.0 equiv) was added. Then PhMgBr (24 mL, 24 mmol, 1 M in THF, 1.2 equiv) was added slowly into the mixture. The solution was stirred for 12 h at rt. The reaction was quenched with saturated aqueous NH₄Cl, and extracted with Et₂O. The combined organic extracts were dried over MgSO₄, filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (EtOAc/PE = 1/5) to yield alcohol as colorless oil.

To a solution of the corresponding alcohol (1.0 equiv) in CH₃CN, periodic acid (2.0 equiv) was added at 0 °C. Finally the pyridinium chlorochromate (0.02 equiv). The reaction mixture was stirred at 35 °C. The reaction was quenched with saturated aqueous NaCl, and extracted with EtOAc. The combined organic extracts were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (EtOAc/PE = 1/1) to yield alcohol as pale yellow oil.

2.2 General procedure for the synthesis of 2-(alkylthio)-1*H*-indole



According to the literature report³, to a solution of appropriate 2-oxindole (10 mmol, 1.0 equiv) in THF (15 mL), Lawesson's reagent (2.14g, 0.53 mmol, 0.53 equiv) was added. The reaction mixture was stirred under refluxing for 1 day. To the mixture was added saturated aq. NaHCO₃ (20 mL) and the aqueous layer was separated and extracted with ethyl acetate (20 mL × 2). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude product was used in the next step without further purification.




Alkyl bromide and alkyl iodide (15 mmol, 1.5 equiv) was added to a solution of corresponding indole-2-thione (10 mmol, 1.0 equiv) and sodium carbonate (1.59g, 15 mmol, 1.5 equiv) in THF (20 mL) and the mixture was stirred for 1 h under refluxing. The reaction mixture was diluted with water (20 mL), extracted with ethyl acetate (20 mL × 2) and the combined extracts were dried by anhydrous Na₂SO₄, filtered and concentrated. The crude product was purified flash column chromatography (300-400 mesh silica gel) to afford the 2-(alkylthio)-1*H*-indole.


2.3 General procedure for the synthesis of 2-(phenylthio)-1*H*-indole

The 2-(phenylthio)-1*H*-indole (**2h**) was synthesized according to the literature⁴.

2.4 General procedure for the synthesis of 2-(ethylthio)-3-methyl-1*H*-indole




To a solution of NCS (2.40 g, 18 mmol, 1.2 equiv) in dry CH₂Cl₂ (15 mL) under nitrogen, the ethanethiol (1.08 mL, 15 mmol, 1.0 equiv) was added dropwise slowly into the mixture. The reaction was carried out for 30 minutes. The reaction solution was filtered with a pad of celite and the filtrate was concentrated in vacuo. The crude product was used in the next step without further purification.



The 2-(ethylthio)-3-methyl-1*H*-indole (**2q**) was synthesized according to the literature report⁵, to a solution of 3-methyl-1*H*-indole (1.31g, 10 mmol, 1.0 equiv) in CH₂Cl₂ (20 mL) was added ethyl hypochlorothioite (1.44g, 15 mmol, 1.5 equiv) dropwise slowly. After stirring for an additional 3 h at room temperature, the reaction was quenched with saturated aq. NaHCO₃ (20 mL). After extraction of the aqueous phase with EtOAc (20 mL × 3), the combined organic extracts were washed with brine (70 mL × 1), dried over anhydrous Na₂SO₄, and concentrated. The crude material was purified by flash chromatography (300-400 mesh silica gel) to afford the 2-(ethylthio)-3-methyl-1*H*-indole.


2.5 General procedure for the synthesis of deuterated substrate



The substrate **2a** (1.63g, 1.0 mmol) was dissolved in MeOD (1.00 mL) and the mixture was stirred at room temperature for 1 hour. The alcohol was removed under vacuum, and the residue was dissolved in another 1 mL MeOD. After another 1 hour at room temperature, the alcohol was evaporated and 1-deuteriothioindole was obtained, and characterized in $\text{CHCl}_3\text{-}d_6$ for ^1H NMR analysis (91% purity).

2.6 General procedure for the synthesis of ligands


The chiral N,N' -dioxides were synthesized from corresponding anilines according to the previous work⁶. 2,6-Dialkoxyanilines and 2,6-diphenoxyaniline were synthesized according to the procedure below.



To a suspension of 1,3-dialkoxy-2-nitrobenzene⁷ or ((2-nitro-1,3-phenylene)bis(oxy))dibenzene⁸ (40.0 mmol, 1.0 equiv.) and NH_4Cl (27.5 g, 420.0 mmol, 10.5 equiv) in CH_3COCH_3 and H_2O (5:1, v/v, 600 mL) was added zinc power (32.1 g, 15.0 equiv) slowly at room temperature. After the substrate was consumed (detected by TLC), the reaction mixture was filtered through a pad of celite and CH_3COCH_3 was removed in vacuum. Subsequently, H_2O (150 mL) was added and the mixture was extracted with CH_2Cl_2 (80 mL \times 3). The organic phase was dried over anhydrous Na_2SO_4 , purified on silica gel to afford the crude product ($\text{Pet/EtOAc} = 8/1$), which was directly used in the next step.

3 Characterization of α -diazo pyrazoleamides

(E)-4-(4-bromophenyl)-2-diazo-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-3-en-1-one (1j)



Red solid; M.p. 117-120 °C.


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.45 – 7.40 (m, 2H), 7.26 – 7.24 (m, 2H), 6.93 (d, J = 16.0 Hz, 1H), 5.99 (d, J = 16.0 Hz, 1H), 2.47 (s, 3H), 2.17 (s, 3H), 1.92 (s, 3H).

$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 160.6, 150.9, 139.5, 135.8, 131.7, 127.4, 120.8, 120.6, 116.9, 114.5, 65.9, 12.2, 12.2, 7.6.

ESI-HRMS: calcd for $\text{C}_{16}\text{H}_{16}\text{N}_4\text{O}^{79}\text{Br}^+([\text{M} + \text{H}]^+) = 359.0502$, found 359.0503. $\text{C}_{16}\text{H}_{16}\text{N}_4\text{O}^{81}\text{Br}^+([\text{M} + \text{H}]^+) = 361.0482$, found 361.0484.

IR (neat): 2923, 2008, 1664, 1489, 1431, 1384, 1358, 1121, 949, 742 cm^{-1} .

(E)-2-diazo-4-(4-iodophenyl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-3-en-1-one (1k)



Red solid; M.p. 130-133 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 7.45 – 7.40 (m, 2H), 7.26 – 7.24 (m, 2H), 6.93 (d, *J* = 16.0 Hz, 1H), 5.99 (d, *J* = 16.0 Hz, 1H), 2.47 (s, 3H), 2.17 (s, 3H), 1.92 (s, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 160.6, 150.9, 139.5, 137.7, 136.4, 127.7, 120.9, 116.9, 114.7, 91.9, 66.0, 12.2, 12.2, 7.6.

ESI-HRMS: calcd for C₁₆H₁₆N₄O⁺ ([M + H]⁺) = 407.0363, found 407.0362.

IR (neat): 2922, 2086, 1663, 1487, 1430, 1384, 1358, 1121, 1003, 739 cm⁻¹.

(E)-2-diazo-4-(4-(trifluoromethyl)phenyl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-3-en-1-one (1l)



Red solid; M.p. 109-111 °C.

¹H NMR (400 MHz, Chloroform-*d*) δ 7.57 – 7.55 (m, 2H), 7.48 – 7.46 (m, 2H), 7.08 (d, *J* = 16.0 Hz, 1H), 6.07 (d, *J* = 16.0 Hz, 1H), 2.47 (s, 3H), 2.18 (s, 3H), 1.92 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 160.4, 151.1, 140.3 (d, *J* = 32.3 Hz), 139.5, 128.6 (d, *J* = 32.3 Hz), 126.0, 125.6 (q, *J* = 3.9 Hz), 120.3, 117.1, 116.8, 66.2, 12.2, 12.2, 7.6; the resonance resulting from diazo group makes the CF₃ carbon undetectable.

¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ -62.43.

ESI-HRMS: calcd for C₁₇H₁₆N₄OF₃⁺ ([M + H]⁺) = 349.1271, found 349.1276.

IR (neat): 2088, 1664, 1611, 1423, 1385, 1322, 1163, 1116, 1066, 946, 852, 732cm⁻¹.

(E)-2-diazo-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)pent-3-en-1-one (1s)



Orange solid; M.p. 63-67 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 7.47 – 7.45 (m, 2H), 7.35 – 7.31 (m, 2H), 7.28 – 7.25 (m, 1H), 6.34 (s, 1H), 2.46 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H), 1.91 (s, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 162.7, 150.7, 142.5, 139.4, 135.7, 128.3, 127.3, 125.9, 116.5, 111.8, 64.5, 17.3, 12.2, 12.1, 7.6.

ESI-HRMS: calcd for C₁₇H₁₉N₄O⁺ ([M + H]⁺) = 295.1553, found 295.1552.

IR (neat): 1695, 1630, 1378, 1351, 1146, 735, 702, 529 cm⁻¹.

(Z/E)-2-diazo-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-3-en-1-one (1a)



Orange solid; M.p. 105-108 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 7.40 – 7.28 (m, 3H), 7.24 – 7.18 (m, 2H), 6.93 (d, *J* = 16.0, 0.36 H), 6.60 (d, *J* = 11.4, 0.64 H), 6.31 (d, *J* = 11.4, 0.64 H), 6.06 (d, *J* = 16.0, 0.36 H), 2.46 (s, 3H), 2.17 (s, 1.08 H), 2.13 (s, 1.92 H), 1.91 – 1.89 (m, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 161.9, 160.8, 150.7, 139.4, 136.8, 135.1, 128.6, 128.5, 127.9, 126.95, 126.93, 125.9, 125.0, 122.2, 116.8, 116.6, 113.9, 113.4, 65.8, 65.3, 12.15, 12.14, 7.5.

IR (neat): 2081, 1659, 1381, 1351, 1263, 748 cm⁻¹.

4 Characterization of 2-(alkylthio)-1*H*-indole

2-(methylthio)-1*H*-indole (2a)



White solid; M.p. 54–56 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 8.01 (s, 1H), 7.54 – 7.52 (m, 1H), 7.28 – 7.23 (m, 1H), 7.18 – 7.14 (m, 1H), 7.11 – 7.07 (m, 1H), 6.54 (dd, *J* = 2.0, 0.8 Hz, 1H), 2.49 (s, 3H).

¹³C{¹H} NMR (100 MHz, CDCl₃) δ 136.9, 131.3, 128.7, 122.2, 120.1, 119.8, 110.4, 105.8, 19.26.

ESI-HRMS: calcd for C₉H₁₀NS⁺ ([M + H]⁺) = 164.0528, found 164.0527.


IR (neat): 3368, 2361, 2335, 1481, 1441, 1314, 747, 633, 465, 432 cm⁻¹.

d-2a



¹H NMR (400 MHz, Chloroform-*d*) δ 8.01 (s, 0.09H), δ 7.54 – 7.52 (m, 1H), 7.28 – 7.24 (m, 1H), 7.18 – 7.14 (m, 1H), 7.11 – 7.07 (m, 1H), 6.55 (s, 1H), 2.49 (s, 3H).

2-(ethylthio)-1*H*-indole (2b)



Pale yellow solid; M.p. 39–41 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 7.91 (s, 1H), 7.47 – 7.45 (m, 1H), 7.15 – 7.12 (m, 1H), 7.09 – 7.05 (m, 1H), 7.02 – 6.98 (m, 1H), 6.53 (dd, *J* = 2.4, 0.8 Hz, 1H), 2.69 (q, *J* = 7.2 Hz, 2H), 1.15 (t, *J* = 7.2 Hz, 3H).

¹³C{¹H} NMR (100 MHz, CDCl₃) δ 136.9, 128.6, 128.5, 122.3, 120.0, 119.9, 110.4, 108.5, 30.5, 15.1.

ESI-HRMS: calcd for C₁₀H₁₂NS⁺ ([M + H]⁺) = 178.0685, found 178.0683.

IR (neat): 3381, 1437, 1337, 1313, 1282, 1257, 1230, 807, 746, 646, 511, 442 cm⁻¹.

2-(propylthio)-1*H*-indole (2c)



Pale yellow oil;


¹H NMR (400 MHz, Chloroform-*d*) δ 7.98 (s, 1H), 7.54 – 7.52 (m, 1H), 7.23 – 7.20 (m, 1H), 7.17 – 7.13 (m, 1H), 7.10 – 7.06 (m, 1H), 6.61 – 6.60 (m, 1H), 2.74(t, *J* = 7.2 Hz, 3H), 1.64 – 1.55 (m, 2H), 0.96 (t, *J* = 7.2 Hz, 3H).

¹³C{¹H} NMR (100 MHz, CDCl₃) δ 136.9, 129.0, 128.6, 122.3, 119.9, 110.5, 108.3, 108.3, 38.4, 23.1, 13.0.

ESI-HRMS: calcd for C₁₁H₁₃NS⁺ ([M + H]⁺) = 192.0841, found 192.0840.

IR (neat): 3400, 2962, 2927, 2870, 1444, 1397, 1339, 1316, 1287, 1233, 793, 743, 643 cm⁻¹.

2-(butylthio)-1*H*-indole (2d)



Pale green oil:


¹H NMR (400 MHz, Chloroform-*d*) δ 7.92 (s, 1H), 7.54 – 7.52 (m, 1H), 7.23 – 6.98 (m, 3H), 6.60 – 6.59 (m, 1H), 2.74(t, *J* = 7.6Hz, 2H), 1.58 – 1.53 (m, 2H), 1.41 – 1.31 (m, 2H), 0.85 (t, *J* = 7.4, 3H).

¹³C{¹H} NMR (100 MHz, CDCl₃) δ 136.8, 129.1, 128.6, 122.2, 119.9, 110.5, 108.1, 36.1, 31.7, 21.5, 13.5.

ESI-HRMS: calcd for $C_{12}H_{16}NS^+ ([M + H]^+)$ = 206.0998, found 206.0996.

IR (neat): 3398, 2957, 2927, 2866, 1443, 1396, 1339, 1315, 1280, 1226, 792, 743, 642 cm⁻¹.

2-(isobutylthio)-1*H*-indole (2e)



Pale yellow oil;


¹H NMR (400 MHz, Chloroform-*d*) δ 7.97 (s, 1H), 7.54 – 7.50 (m, 1H), 7.22 – 7.19 (m, 1H), 7.16 – 7.12 (m, 1H), 7.10 – 7.05 (m, 1H), 6.60 – 6.56 (m, 1H), 2.67 (d, *J* = 7.2 Hz, 2H), 1.83 – 1.73 (m, 1H), 0.98 (d, *J* = 6.8 Hz, 6H).

¹³C{¹H} NMR (100 MHz, CDCl₃) δ 136.8, 129.7, 128.6, 122.2, 119.9, 119.9, 110.4, 107.8, 45.4, 28.5, 21.6.

ESI-HRMS: calcd for $C_{12}H_{16}NS^+ ([M + H]^+)$ = 206.0998, found 206.0996.

IR (neat): 3396, 2956, 2923, 2868, 1442, 1390, 1338, 1280, 1238, 791, 741, 641, 483, 443 cm^{-1} .

2-(dodecylthio)-1*H*-indole (2f)



White solid; M.p. 44-46 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 8.06 (s, 1H), 7.57 – 7.55 (m, 1H), 7.33 – 7.31 (m, 1H), 7.21 – 7.17 (m, 1H), 7.13 – 7.09 (m, 1H), 6.63 (d, *J* = 1.6 Hz, 1H), 2.83 (t, *J* = 7.2 Hz 2H), 1.66 – 1.61 (m, 2H), 1.43 – 1.36 (m, 2H), 1.31 – 1.26 (m, 16H), 0.89 (t, *J* = 7.2 Hz, 3H).

$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 136.93, 129.2, 128.7, 122.4, 120.1, 120.0, 110.4, 108.4, 36.7, 31.9, 29.9, 29.6, 29.6, 29.5, 29.3, 29.1, 28.5, 22.7, 14.1.

ESI-HRMS: calcd for $C_{20}H_{32}NS^+$ ($[M + H]^+$) = 318.2250, found 318.2245.

IR (neat): 3372, 2914, 2848, 1467, 1441, 1273, 750, 716, 637, 485 cm^{-1} .

2-(benzylthio)-1*H*-indole (2g)



Pale yellow solid; M.p. 76–78 °C.


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.76 (s, 1H), 7.55 – 7.52 (m, 1H), 7.28 – 7.23 (m, 3H), 7.22 – 7.13 (m, 4H), 7.10 – 7.06 (m, 1H), 6.58 (dd, J = 2.0, 0.8 Hz, 1H), 3.98 (s, 2H).

$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, CDCl_3) δ 138.3, 137.0, 128.8, 128.6, 128.4, 128.1, 127.3, 122.6, 120.3, 120.0, 110.5, 109.5, 41.9.

ESI-HRMS: calcd for $C_{15}H_{14}NS^+$ ($[M + H]^+$) = 240.0841, found 240.0839.

IR (neat): 3383, 1488, 1447, 1340, 1274, 923, 746, 706, 634, 470, 637 cm^{-1} .

5-chloro-2-(methylthio)-1*H*-indole (2i)



White solid; M.p. 89–91 °C.


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.04 (s, 1H), 7.50 – 7.49 (m, 1H), 7.20 – 7.17 (m, 1H), 7.13 – 7.10 (m, 1H), 6.46 – 6.45 (m, 1H), 2.51 (s, 3H).

$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 135.1, 133.4, 129.8, 125.7, 122.3, 119.1, 111.2, 104.7, 18.8.

ESI-HRMS: calcd for $C_9H_9NS^{35}\text{Cl}^+$ ($[M + H]^+$) = 198.0139, found 198.0138. $C_9H_9NS^{37}\text{Cl}^+$ ($[M + H]^+$) = 200.0109, found 200.0106.

IR (neat): 3389, 1442, 1396, 1316, 1060, 914, 866, 800, 761, 687, 636, 587, 459, 432 cm^{-1} .

5-bromo-2-(methylthio)-1*H*-indole (2j)



Pale yellow solid; M.p. 93–95 °C.


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.05 (s, 1H), 7.64 (d, J = 1.8 Hz, 1H), 7.25 – 7.21 (m, 1H), 7.15 – 7.13 (m, 1H), 6.44 – 6.43 (m, 1H), 2.50 (s, 3H).

$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, CDCl_3) δ 135.4, 133.3, 130.5, 124.9, 122.2, 113.3, 111.7, 104.5, 18.8.

ESI-HRMS: calcd for $C_9H_9NS^{79}\text{Br}^+$ ($[M + H]^+$) = 241.9634, found 241.9630. $C_9H_9NS^{81}\text{Br}^+$ ($[M + H]^+$) = 243.9613, found 243.9609.

IR (neat): 3385, 1562, 1434, 1394, 1314, 1268, 1047, 866, 798, 759, 663, 635, 581, 466 cm^{-1} .

5-methoxy-2-(methylthio)-1*H*-indole (2k)



Pale yellow solid; M.p. 78–80 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 8.07 (s, 1H), 7.18 – 7.16 (m, 1H), 7.05 – 7.03 (m, 1H), 6.88 – 6.85 (m, 1H), 6.51 (dd, *J* = 2.0, 0.8 Hz, 1H), 3.87 (s, 3H), 2.49 (s, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 154.2, 132.1, 131.9, 129.2, 112.4, 111.2, 105.6, 101.6, 55.8, 19.3.

ESI-HRMS: calcd for C₁₀H₁₂NOS⁺ ([M + H]⁺) = 194.0634, found 194.0633.

IR (neat): 3392, 2923, 1621, 1582, 1506, 1469, 1440, 1218, 1193, 1155, 1208, 973, 839, 795 cm⁻¹.

6-fluoro-2-(methylthio)-1*H*-indole (2l)



White solid; M.p. 76–78 °C.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.04 (s, 1H), 7.44 (dd, *J* = 8.8, 5.4 Hz, 1H), 7.01 – 6.98 (m, 1H), 6.89 – 6.84 (m, 1H), 6.54 – 6.53 (m, 1H), 2.49 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 160.0 (d, *J* = 237.2 Hz), 136.7 (d, *J* = 12.4 Hz), 131.4 (d, *J* = 3.4 Hz), 125.2, 120.6 (d, *J* = 10.0 Hz), 108.9 (d, *J* = 24.3 Hz), 106.3, 96.9 (d, *J* = 26.1 Hz), 19.5.

¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ -120.41.

ESI-HRMS: calcd for C₉H₉NSF⁺ ([M + H]⁺) = 182.0434, found 182.0431.

IR (neat): 3356, 1618, 1485, 1443, 1381, 1338, 1279, 1220, 1138, 960, 932, 843, 811, 758, 639, 612, 480, 441 cm⁻¹.

6-chloro-2-(methylthio)-1*H*-indole (2m)



White solid; M.p. 127–128 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 8.00 (s, 1H), 7.41 (d, 8.4 Hz, 1H), 7.26 – 7.24 (m, 1H), 7.07 – 7.04 (m, 1H), 6.50 – 6.49 (m, 1H), 2.49 (s, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 137.1, 132.4, 128.0, 127.3, 120.8, 120.6, 110.3, 105.5, 19.0.

ESI-HRMS: calcd for C₉H₉NS³⁵Cl⁺ ([M + H]⁺) = 198.0139, found 198.0138. C₉H₉NS³⁷Cl⁺ ([M + H]⁺) = 200.0109, found 200.0106.

IR (neat): 3352, 1436, 1369, 1333, 1290, 1059, 912, 854, 811, 761, 734, 638, 481, 434 cm⁻¹.

6-bromo-2-(methylthio)-1*H*-indole (2n)



White solid; M.p. 136–138 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 8.01 (s, 1H), 7.44 – 7.43 (m, 1H), 7.39 – 7.37 (m, 1H), 7.21 – 7.19 (m, 1H), 6.51 – 6.49 (m, 1H), 2.51 (s, 3H).

¹³C{¹H} NMR (100 MHz, CDCl₃) δ 137.5, 132.5, 127.6, 123.4, 120.9, 115.6, 113.3, 105.5, 18.9.

ESI-HRMS: calcd for C₉H₉NS⁷⁹Br⁺ ([M + H]⁺) = 241.9634, found 241.9631. C₉H₉NS⁸¹Br⁺ ([M + H]⁺) = 243.9613, found 243.9610

IR (neat): 3348, 2361, 2335, 1455, 1266, 1047, 900, 855, 811, 757, 638, 508, 483, 428 cm⁻¹.

7-bromo-2-(methylthio)-1*H*-indole (2o)



Pale green solid; M.p. 55-57 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 8.23 (s, 1H), 7.46 (d, *J* = 7.6 Hz, 1H), 7.32 – 7.30 (m, 1H), 6.98 (t, *J* = 7.6 Hz, 1H), 6.60 (d, *J* = 2.0 Hz, 1H), 2.54 (s, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 135.5, 132.7, 129.8, 124.4, 121.3, 118.9, 106.4, 103.7, 19.0.

ESI-HRMS: calcd for C₉H₉NS⁷⁹Br⁺ ([M + H]⁺) = 241.9634, found 241.9630. C₉H₉NS⁸¹Br⁺ ([M + H]⁺) = 243.9613, found 243.9610

IR (neat): 3311, 2361, 2335, 1416, 1329, 1273, 965, 810, 757, 659, 527 cm⁻¹.

6-chloro-5-(2-chloroethyl)-2-(methylthio)-1*H*-indole (2p)



White solid; M.p. 96-97 °C.


¹H NMR (400 MHz, Chloroform-*d*) δ 7.99 (s, 1H), 7.40 (s, 1H), 7.31 (s, 1H), 6.47 – 7.46 (m, 1H), 3.76 (t, *J* = 7.6 Hz, 2H), 3.26 (t, *J* = 7.6 Hz, 2H), 2.50 (s, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 136.3, 133.1, 128.0, 127.8, 127.1, 121.7, 111.1, 105.1, 43.9, 37.3, 18.9.

ESI-HRMS: calcd for C₁₁H₁₂NS³⁵Cl₂⁺ ([M + H]⁺) = 260.0062, found 260.0060. C₁₁H₁₂NS³⁵Cl³⁷C⁺ ([M + H]⁺) = 262.0033, found 262.0029. C₁₁H₁₂NS³⁷Cl₂⁺ ([M + H]⁺) = 264.0003, found 263.9998.

IR (neat): 3356, 1453, 1320, 1267, 994, 913, 877, 758, 636, 484 cm⁻¹.

2-(ethylthio)-3-methyl-1*H*-indole (2q)



Pale yellow oil;


¹H NMR (400 MHz, Chloroform-*d*) δ 7.89 (s, 1H), 7.53 – 7.51 (m, 1H), 7.23 – 7.15 (m, 2H), 7.11 – 7.07 (m, 1H), 2.69 (q, *J* = 8.8 Hz, 2H), 2.37 (s, 3H), 1.18 (t, *J* = 7.4 Hz, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 136.2, 128.5, 124.5, 122.8, 119.3, 119.0, 117.9, 110.5, 30.7, 15.3, 9.5.

ESI-HRMS: calcd for C₁₁H₁₄NS⁺ ([M + H]⁺) = 192.0841, found 192.0844.

IR (neat): 3401, 2920, 1446, 1374, 1331, 966, 740, 647 cm⁻¹.

2-(ethylthio)-1-methyl-1*H*-indole (2r)



Pale yellow oil;


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.56 – 7.53 (m, 1H), 7.26 – 7.17 (m, 2H), 7.10 – 7.06 (m, 1H), 6.66 (s, 1H), 3.76 (s, 3H), 2.78 – 2.72 (m, 2H), 1.26 – 1.22 (m, 3H).

$^{13}\text{C}\{\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 138.2, 131.3, 127.4, 121.9, 120.1, 119.6, 109.4, 108.2, 30.5, 29.8, 14.6.

ESI-HRMS: calcd for $\text{C}_{11}\text{H}_{14}\text{NS}^+$ ($[\text{M} + \text{H}]^+$) = 192.0841, found 192.0839.

IR (neat): 2923, 1454, 1317, 1258, 785, 739, 625 cm^{-1} .

5 Characterization of chiral *N,N'*-dioxides



L₂-Pi(OMe)₂


White power. M.p. 117–120 °C. $[\alpha]^{22}_D = +30.4$ ($c = 0.26$, in MeOH).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 11.75 (s, 2H), 7.14 (t, $J = 8.4$ Hz, 2H), 6.52 (d, $J = 8.4$ Hz, 4H), 4.50 – 4.37 (m, 2H), 4.07 – 3.95 (m, 2H), 3.76 (s, 12H), 3.65 – 3.57 (m, 2H), 3.53 – 3.45 (m, 2H), 3.09 (td, $J = 12.0, 2.8$ Hz, 2H), 2.72 – 2.57 (m, 2H), 2.50 – 2.38 (m, 2H), 2.12 – 2.01 (m, 2H), 1.90 – 1.78 (m, 2H), 1.67 – 1.56 (m, 2H), 1.46 – 1.30 (m, 2H).

$^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 167.0, 155.7, 127.8, 113.4, 104.4, 75.1, 65.9, 62.1, 56.0, 25.9, 21.9, 20.4.

ESI-HRMS: calcd for $\text{C}_{30}\text{H}_{43}\text{N}_4\text{O}_8^+$ ($[\text{M} + \text{H}]^+$) = 587.3075, found 587.3080.

IR (neat): 1676, 1594, 1539, 1477, 1257, 1112 cm^{-1} .



L₂-Pi(OEt)₂

White foam. M.p. 87–90 °C. $[\alpha]^{22}_D = +24.4$ ($c = 0.36$, in MeOH).


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 11.76 (s, 2H), 7.09 (t, $J = 8.4$ Hz, 2H), 6.50 (d, $J = 8.4$ Hz, 4H), 4.40 (td, $J = 9.2, 8.7, 3.8$ Hz, 2H), 4.04 – 3.92 (m, 10H), 3.64 – 3.55 (m, 2H), 3.52 – 4.42 (m,

2H), 3.08 (td, $J = 12.0, 2.8$ Hz, 2H), 2.69 – 2.59 (m, 2H), 2.48 – 2.38 (m, 2H), 2.07 – 2.01 (m, 2H), 1.87 – 1.78 (m, 2H), 1.63 – 1.54 (m, 2H), 1.36 (t, $J = 7.2$ Hz, 14H).

^{13}C NMR (100 MHz, Chloroform-*d*) δ 166.6, 154.9, 127.4, 114.2, 105.5, 75.1, 65.8, 64.4, 62.1, 25.9, 22.0, 20.3, 15.0.

ESI-HRMS: calcd for $\text{C}_{34}\text{H}_{51}\text{N}_4\text{O}_8^+ ([\text{M} + \text{H}]^+) = 643.3701$, found 643.3706.

IR (neat): 1680, 1591, 1538, 1465, 1254, 1118, 1093 cm⁻¹.




White foam. M.p. 88–91 °C. $[\alpha]^{22}\text{D} = -19.6$ ($c = 0.28$, in CH_2Cl_2).

^1H NMR (400 MHz, Chloroform-*d*) δ 11.65 (s, 2H), 7.09 (t, $J = 8.4$ Hz, 2H), 6.53 (d, $J = 8.4$ Hz, 4H), 4.56 – 4.45 (m, 4H), 4.33 (s, 2H), 4.18 – 4.00 (m, 2H), 3.70 – 3.37 (m, 4H), 3.09 (q, $J = 12.0$ Hz, 2H), 2.72 – 2.58 (m, 2H), 2.50 – 2.36 (m, 2H), 2.06 – 2.00 (m, 2H), 1.86 – 1.75 (m, 2H), 1.62 – 1.48 (m, 2H), 1.33 (dd, $J = 6.0, 3.2$ Hz, 26H).

^{13}C NMR (100 MHz, Chloroform-*d*) δ 166.1, 154.0, 127.1, 115.8, 106.5, 75.3, 71.2, 65.4, 62.2, 25.9, 22.4, 21.9, 20.2.

ESI-HRMS: calcd for $\text{C}_{38}\text{H}_{59}\text{N}_4\text{O}_8^+ ([\text{M} + \text{H}]^+) = 699.4327$, found 699.4326.

IR (neat): 1685, 1593, 1534, 1467, 1254, 1115, 1067 cm⁻¹.




White foam. M.p. 88–91 °C. $[\alpha]^{22}\text{D} = +43.6$ ($c = 0.58$, in MeOH).

^1H NMR (400 MHz, Chloroform-*d*) δ 11.69 (s, 2H), 7.06 (t, $J = 7.6$ Hz, 2H), 6.48 – 6.46 (m, 4H), 4.48 – 4.10 (m, 4H), 3.64 – 3.54 (m, 12H), 3.09 – 2.41 (m, 5H), 2.07 – 1.39 (m, 13H), 0.98 – 0.92 (m, 24H).

^{13}C NMR (100 MHz, CDCl_3) δ 166.2, 154.8, 127.2, 113.4, 104.6, 75.4, 74.7, 65.5, 61.6, 28.1, 25.9, 20.2, 19.2, 19.1.

ESI-HRMS: calcd for $\text{C}_{42}\text{H}_{67}\text{N}_4\text{O}_8^+ ([\text{M} + \text{H}]^+) = 755.4953$, found 755.4954.

IR (neat): 1687, 1596, 1537, 1463, 1257, 1101 cm⁻¹.



L₂-Pi(Oipentyl)₂


White foam. M.p. 88–92 °C. $[\alpha]^{21}_D = +53.0$ ($c = 0.26$, in MeOH).

¹H NMR (400 MHz, Chloroform-*d*) δ 11.63 (s, 2H), 7.11 (t, $J = 8.3$ Hz, 2H), 6.51 (d, $J = 8.5$ Hz, 4H), 4.43 (s, 2H), 4.08 – 3.92 (m, 8H), 3.58 (s, 4H), 3.11 – 1.40 (m, 28H), 0.92 – 0.91 (m, 24H).

¹³C NMR (100 MHz, CDCl₃) δ 166.3, 154.9, 127.39, 113.6, 104.9, 75.1, 67.0, 65.3, 61.7, 37.8, 25.8, 24.8, 22.5, 21.8, 20.1.

ESI-HRMS: calcd for C₄₆H₇₅N₄O₈⁺ ([M + H]⁺) = 811.5579, found 811.5577.

IR (neat): 1679, 1593, 1537, 1462, 1253, 1096 cm⁻¹.



L₂-Pi(Obn)₂


White foam. M.p. 88–91 °C. $[\alpha]^{21}_D = +46.7$ ($c = 0.42$, in MeOH).

¹H NMR (400 MHz, Chloroform-*d*) δ 12.04 (s, 2H), 7.50 – 7.43 (m, 8H), 7.38 (t, $J = 7.2$ Hz, 8H), 7.34 – 7.29 (m, 4H), 7.11 (t, $J = 8.4$ Hz, 2H), 6.62 (d, $J = 8.4$ Hz, 4H), 5.08 (s, 8H), 4.00 (br, 2H), 3.70 (br, 2H), 3.3 – 2.7 (m, 4H), 2.60 (t, $J = 12.0$ Hz, 2H), 2.44 – 2.28 (m, 2H), 2.20 – 2.06 (m, 2H), 1.73 – 1.64 (m, 2H), 1.57 – 1.44 (m, 2H), 1.25 – 1.14 (m, 2H), 1.05 – 0.85 (m, 2H).

¹³C NMR (100 MHz, CDCl₃) δ 166.5, 154.8, 136.9, 128.5, 128.0, 127.3, 114.5, 106.1, 74.5, 70.7, 64.8, 62.0, 25.9, 21.5, 20.0.

ESI-HRMS: calcd for C₅₄H₅₉N₄O₈⁺ ([M + H]⁺) = 891.4327, found 891.4316.

IR (neat): 1683, 1595, 1534, 1464, 1378, 1261, 1102, 744, 698 cm⁻¹.



L₂-Pi(OPh)₂

White foam. M.p. 98–101 °C. $[\alpha]^{21}_D = +39.6$ ($c = 0.26$, in MeOH).

¹H NMR (400 MHz, Chloroform-*d*) δ 12.12 (s, 2H), 7.36 – 7.28 (m, 8H), 7.13 – 7.00 (m, 14H), 6.57 (d, $J = 8.4$ Hz, 4H), 4.74 – 4.30 (m, 1H), 4.05 – 3.70 (m, 3H), 3.25 – 2.88 (m, 3H), 2.59 (t, $J = 12.0$ Hz, 2H), 2.16 – 1.98 (m, 4H), 1.60 – 1.38 (m, 4H), 1.29 – 1.18 (m, 1H), 1.09 – 0.62 (m, 4H).

¹³C NMR (100 MHz, CDCl₃) δ 167.0, 156.5, 154.0, 129.9, 127.7, 123.9, 119.3, 118.8, 113.2, 100.0, 74.9, 65.3, 62.6, 25.4, 21.5, 20.0.


ESI-HRMS: calcd for C₅₀H₅₁N₄O₈⁺ ([M + H]⁺) = 835.3701, found 835.3701.

IR (neat): 1683, 1579, 1518, 1486, 1456, 1238, 1205, 1161, 1023, 752, 691 cm⁻¹.

6 Typical experimental procedure for the asymmetric [3,3]-rearrangement

6.1 Optimization of the reaction conditions


Table S1: Screen of metal salts



| entry ^a | metal salt | yield (%) ^b | ee (%) ^c |
|--------------------|----------------------|------------------------|---------------------|
| 1 | Fe(OTf) ₂ | 34 | 7 |
| 2 | Fe(OTf) ₃ | 43 | 6 |
| 3 | Co(OTf) ₂ | 83 | 2 |
| 4 | Ni(OTf) ₂ | 80 | 13 |
| 5 | Cu(OTf) ₂ | 54 | 1 |

^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-1*H*-indole **2b** (0.1 mmol), diazo compound **1a** (0.1 mmol), metal salt (10 mol%), **L₂-PrPr₂** (10 mol%) and CH₂Cl₂ (0.1 M) at 35 °C. ^b Isolated yields of **3ab**. ^c Determined by HPLC on a chiral stationary phase.

Table S2: Screening of chiral *N,N'*-dioxide ligands



| entry ^a | ligand | yield (%) ^b | ee (%) ^c |
|--------------------|---------------------------------------|------------------------|---------------------|
| 1 | L₂-PrPr₂ | 80 | 13 |
| 2 | L₃-PrPr₂ | 75 | 18 |
| 3 | L₂-PiPr₂ | 93 | 21 |
| 4 | L₃-PiPr₂ | 96 | 31 |
| 5 | L₂-RaPr₂ | 50 | 14 |
| 6 | L₃-RaPr₂ | 74 | 29 |
| 7 | L₃-PePr₂ | 40 | 25 |


^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-1*H*-indole **2b** (0.1 mmol), diazo compound **1a** (0.1 mmol), Ni(OTf)₂ (10 mol%), **Ligand** (10 mol%) and CH₂Cl₂ (0.1 M) at 35 °C. ^b Isolated yields of **3ab**. ^c Determined by HPLC on a chiral stationary phase.

Table S3: Screen of metal salts

| entry ^a | metal salt | yield (%) ^b | ee (%) ^c |
|--------------------|---|------------------------|---------------------|
| 1 | Ni(OTf) ₂ | 96 | 31 |
| 2 | Ni(NTf ₂) ₂ | 88 | 4 |
| 3 | Ni(BF ₄) ₂ .6H ₂ O | 85 | 13 |
| 4 | Ni(ClO ₄) ₂ .6H ₂ O | 74 | 1 |
| 5 | Ni(AcAc) ₂ .2H ₂ O | 22 | 4 |
| 6 | Ni(C ₂ O ₄).2H ₂ O | 29 | 9 |
| 7 ^d | Ni(DME)Br ₂ | 83 | 28 |

^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-1*H*-indole **2b** (0.1 mmol), diazo compound **1a** (0.1 mmol), metal salt (10 mol%), **L₃-PiPr₂** (10 mol%) and CH₂Cl₂ (0.1 M) at 35 °C. ^b Isolated yields of **3ab**. ^c Determined by HPLC on a chiral stationary phase. ^d DME = 1,2-dimethoxyethane.


Table S4: Screening of chiral *N,N'*-dioxide ligands



| entry ^a | ligand | yield (%) ^b | ee (%) ^c |
|--------------------|---|------------------------|---------------------|
| 1 | L₂-Pi(OMe)₂ | 94 | 33 |
| 2 | L₂-Pi(OEt)₂ | 87 | 17 |
| 3 | L₂-Pi(OiPr)₂ | 93 | 31 |
| 4 | L₂-Pi(OiBu)₂ | 93 | 46 |
| 5 | L₂-Pi(OPh)₂ | 84 | 29 |
| 6 | L₂-Pi(OBn)₂ | 81 | 21 |
| 7 | L₃-PiMe₂ | 77 | 13 |
| 8 | L₃-PiEt₂ | 86 | 17 |
| 9 | L₃-PiMe₃ | 83 | 24 |
| 10 | L₃-PiEt₂Me | 87 | 26 |
| 11 | L₃-PiPr₃ | 89 | 23 |
| 12 | L₃-PiBu | 53 | race |
| 13 | L₃-PiCHPh₂ | 52 | race |
| 14 | L₄-PiMe₂tBu | 12 | 18 |
| 15 | L₄-PiPr₃ | 19 | 4 |

^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-1*H*-indole **2b** (0.1 mmol), diazo compound **1a** (0.1 mmol), $\text{Ni}(\text{OTf})_2$ (10 mol%), **Ligand** (10 mol%) and CH_2Cl_2 (0.1 M) at 35 °C. ^b Isolated yields of **3ab**. ^c Determined by HPLC on a chiral stationary phase.

Table S5: Screening of solvents and temperature



| | | | | | |
|-----------------|--------------------------------------|-----|-----|----|----|
| 2 ^d | PhCH ₃ | 35 | 2 h | 75 | 10 |
| 3 ^d | Et ₂ O | 35 | 2 h | 85 | 2 |
| 4 ^d | CH ₃ COOMe | 35 | 2 h | 81 | 16 |
| 5 ^d | CH ₃ CN | 35 | 2 h | 65 | 17 |
| 6 ^d | CH ₂ Cl ₂ | 35 | 2 h | 90 | 50 |
| 7 ^d | CHCl ₃ | 35 | 2 h | 88 | 60 |
| 8 ^d | CH ₂ ClCH ₂ Cl | 35 | 2 h | 72 | 42 |
| 9 ^d | CHCl ₂ CH ₂ Cl | 35 | 2 h | 92 | 53 |
| 10 ^d | CHCl ₂ CHCl ₂ | 35 | 2 h | 97 | 51 |
| 11 ^e | CH ₂ Cl ₂ | 0 | 1 d | 85 | 63 |
| 12 ^e | CH ₂ Cl ₂ | -10 | 1 d | 91 | 77 |
| 13 ^e | CH ₂ Cl ₂ | -20 | 2 d | 85 | 80 |
| 14 ^e | CH ₂ Cl ₂ | -30 | 4 d | 10 | 50 |
| 15 ^e | CH ₂ Cl ₂ | -40 | 4 d | 6 | 22 |
| 16 | CHCl ₃ | -20 | 2 d | 84 | 90 |

^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-1*H*-indole **2b** (0.1 mmol), diazo compound **1a** (0.1 mmol), Ni(OTf)₂ (10 mol%), L₂-Pi(O*i*Bu)₂ (10 mol%) and CHCl₃ (0.1 M) at -20 °C. ^b Isolated yields of **3ab**. ^c Determined by HPLC on a chiral stationary phase. ^d The reactions were carried out at 35 °C. ^e The reactions were carried out in CH₂Cl₂ (0.1 M).

Table S6: Screening of the reaction concentration

| entry ^a | concentration | time | 3ab | |
|--------------------|---------------|------|------------------------|---------------------|
| | | | yield (%) ^b | ee (%) ^c |
| 1 | 0.2 M | 31 h | 87 | 92 |
| 2 | 0.1 M | 2 d | 84 | 90 |
| 3 | 0.05 M | 3 d | 81 | 87 |

^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-1*H*-indole **2b** (0.1 mmol), diazo compound **1a** (0.1 mmol), Ni(OTf)₂ (10 mol%), L₂-Pi(O*i*Bu)₂ (10 mol%) and CHCl₃ (0.2 M) at -20 °C. ^b Isolated yields of **3ab**. ^c Determined by HPLC on a chiral stationary phase.

Table S7: Screening of the catalyst loading

| entry ^a | x | time | 3ab | |
|--------------------|-----|------|------------------------|---------------------|
| | | | yield (%) ^b | ee (%) ^c |
| 1 | 10 | 31 h | 86 | 92 |
| 2 | 5.0 | 3 d | 65 | 91 |

| | | | | |
|---|-----|-----|----|----|
| 3 | 2.5 | 3 d | 39 | 92 |
|---|-----|-----|----|----|

^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-1*H*-indole **2b** (0.1 mmol), diazo compound **1a** (0.1 mmol), Ni(OTf)₂ (*x* mol%), **L₂-Pi(O*i*Bu)₂** (*x* mol%) and CHCl₃ (0.2 M) at -20 °C. ^b Isolated yields of **3ab**. ^c Determined by HPLC on a chiral stationary phase.

Table S8: Screening of additives

| entry ^a | additive | time | yield (%) ^b | ee (%) ^c | | | |
|--------------------|--------------------------------|------|------------------------|---------------------|----------------|----------------|----------------|
| | | | | | 3 Å MS (10 mg) | 4 Å MS (10 mg) | 5 Å MS (10 mg) |
| 1 | 3 Å MS (10 mg) | 30 h | 68 | 90 | | | |
| 2 | 4 Å MS (10 mg) | 30 h | 68 | 88 | | | |
| 3 | 5 Å MS (10 mg) | 30 h | 70 | 91 | | | |
| 4 | NaBArF ₄ (10 mol%) | 36 h | 59 | 80 | | | |
| 5 | <i>m</i> -CPBA (10 mol%) | 27 h | 79 | 90 | | | |
| 6 | 3-Chlorobenzoic acid (10 mol%) | 27 h | 85 | 91 | | | |
| 7 | 3-Nitrobenzoic acid (10 mol%) | 27 h | 77 | 86 | | | |

^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-1*H*-indole **2b** (0.1 mmol), diazo compound **1a** (0.1 mmol), Ni(OTf)₂ (10 mol%), **L₂-Pi(O*i*Bu)₂** (10 mol%), additives and CHCl₃ (0.2 M) at -20 °C.

^b Isolated yields of **3ab**. ^c Determined by HPLC on a chiral stationary phase.

Table S9: Screening of the R group of 2-(alkylthio)-1*H*-indole **2**

| entry ^a | R | time | yield (%) | ee (%) ^b | PG |
|--------------------|----|------|-----------|---------------------|----------------------------|
| | | | | | 3aa, R = Me 3ab, R = Et |
| 1 ^c | Me | 20 h | 90 | 96 | |
| 2 ^d | Et | 31 h | 87 | 92 | |

^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-1*H*-indole **2b** (0.1 mmol), diazo compound **1a** (0.1 mmol), Ni(OTf)₂ (10 mol%), **L₂-Pi(O*i*Bu)₂** (10 mol%), and CHCl₃ (0.2 M) at -20 °C. ^b Determined by HPLC on a chiral stationary phase. ^c Isolated yields of **3aa**. ^d Isolated yields of **3ab**.


Table S10: Screen of the ratio of **1a** and **2a**

| ratio ^a | time | yield (%) ^b | ee (%) ^c | PG |
|--------------------|------|------------------------|---------------------|----------------------------|
| | | | | 3aa, R = Me 3ab, R = Et |
| 1 ^c | 20 h | 90 | 96 | |
| 2 ^d | 31 h | 87 | 92 | |

| entry ^a | 1a:2a | yield (%) ^b | ee (%) ^c |
|--------------------|--------------|------------------------|---------------------|
| 1 | 1.0:1.0 | 90 | 96 |
| 2 ^d | 1.0:1.2 | 94 | 96 |
| 3 ^e | 1.0:1.5 | 94 | 95 |
| 4 ^f | 1.0:2.0 | 91 | 95 |

^a Unless otherwise noted, the reactions were carried out with 2-(methylthio)-1*H*-indole **2a** (0.1 mmol), diazo compound **1a** (0.1 mmol), Ni(OTf)₂ (10 mol%), **L₂-Pi(O*i*Bu)₂** (10 mol%), and CHCl₃ (0.2 M) at -20 °C. ^b Isolated yields of **3aa**. ^c Determined by HPLC on a chiral stationary phase. ^d **2a** (0.12 mmol) was used. ^e **2a** (0.15 mmol) was used. ^f **2a** (0.20 mmol) was used.


Table S11: Screen of other representative chiral ligand



| entry ^a | ligand | yield (%) ^b | ee (%) |
|--------------------|-----------|------------------------|--------|
| 1 | BINAP | N.R. | N.D. |
| 2 | BINOL | N.R. | N.D. |
| 3 ^c | CPA-1 | trace | N.D. |
| 4 | tBu-Box | N.R. | N.D. |
| 5 | iPr-Pybox | N.R. | N.D. |
| 6 ^c | (+)-CSA | trace | N.D. |

^a Unless otherwise noted, the reactions were carried out with 2-(methylthio)-1*H*-indole **2a** (0.12 mmol), diazo compound **1a** (0.1 mmol), Ni(OTf)₂ (10 mol%), **Ligand** (10 mol%), and CHCl₃ (0.2 M) at -20 °C for 2 d. ^b Isolated yields of **3aa**. ^c Used as catalyst without Ni(OTf)₂.


Table S12: Variations from standard conditions when **3aa** is derived to **4aa**



| entry ^a | varyations | yield of 3aa (%) ^b | yield of 4aa (%) ^c | ee of 4aa (%) ^d |
|--------------------|--|-------------------------------|-------------------------------|----------------------------|
| 1 ^e | without Ni(OTf) ₂ | N.R. | N.R. | N.D. |
| 2 ^e | without $\text{L}_2\text{-Pi(OiBu)}_2$ | N.R. | N.R. | N.D. |
| 3 | none | 94 | 87 | 96 |
| 4 ^e | Fe(OTf) ₂ instead of Ni(OTf) ₂ | trace | trace | N.D. |
| 5 | Cu(OTf) ₂ instead of Ni(OTf) ₂ | 38 | 27 | 37 |
| 6 | Co(OTf) ₂ instead of Ni(OTf) ₂ | 82 | 82 | 79 |
| 7 | Ni(NTf ₂) ₂ instead of Ni(OTf) ₂ | 92 | 85 | 95 |
| 8 ^f | Ni(DME)Br ₂ instead of Ni(OTf) ₂ | 92 | 84 | 94 |
| 9 | $\text{L}_2\text{-PiMe}_2$ instead of $\text{L}_2\text{-Pi(OiBu)}_2$ | 41 | 24 | 33 |
| 10 | $\text{L}_2\text{-PiEt}_2$ instead of $\text{L}_2\text{-Pi(OiBu)}_2$ | 99 | 84 | 50 |
| 11 | $\text{L}_2\text{-PiPr}_2$ instead of $\text{L}_2\text{-Pi(OiBu)}_2$ | 86 | 68 | 61 |
| 12 | $\text{L}_2\text{-Pi(OMe)}_2$ instead of $\text{L}_2\text{-Pi(OiBu)}_2$ | 96 | 67 | 58 |
| 13 | $\text{L}_2\text{-Pi(OEt)}_2$ instead of $\text{L}_2\text{-Pi(OiBu)}_2$ | 89 | 64 | 62 |
| 14 | $\text{L}_2\text{-Pi(OiPr)}_2$ instead of $\text{L}_2\text{-Pi(OiBu)}_2$ | 83 | 61 | 94 |
| 15 | $\text{L}_2\text{-Pi(Oipentyl)}_2$ instead of $\text{L}_2\text{-Pi(OiBu)}_2$ | 86 | 74 | 77 |
| 16 | CH ₂ Cl ₂ instead of CHCl ₃ | 76 | 54 | 90 |
| 17 | THF instead of CHCl ₃ | 13 | 10 | 14 |

^a Unless otherwise noted, the reactions were carried out with 2-(methylthio)-1*H*-indole **2a** (0.12 mmol), diazo compound **1a** (0.1 mmol), Ni(OTf)₂ (10 mol%), $\text{L}_2\text{-Pi(OiBu)}_2$ (10 mol%), and CHCl₃ (0.2 M) at -20 °C. ^b Isolated yields of **3aa**. ^c Isolated yields of **4aa**. ^d Determined by HPLC on a chiral stationary phase. ^e NR = no reaction, ND = not detected. ^f DME = 1,2-dimethoxyethane.

Table S13: The detailed screening of conditions for substrate **2q**




| entry ^a | metal salt | ligand | T (°C) | yield (%) ^b | dr ^c | ee (%) ^d |
|--------------------|------------------------------------|--------------------------------|--------|------------------------|-----------------|---------------------|
| 1 | Ni(OTf) ₂ | $\text{L}_2\text{-Pi(OiBu)}_2$ | 35 | 83 | 70:30 | 6/12 |
| 2 | Ni(NTf ₂) ₂ | $\text{L}_2\text{-Pi(OiBu)}_2$ | 35 | 87 | 60:40 | 14/race |
| 3 ^e | Ni(DME) ₂ | $\text{L}_2\text{-Pi(OiBu)}_2$ | 35 | 56 | 40:60 | 13/6 |
| 4 | Co(OTf) ₂ | $\text{L}_2\text{-Pi(OiBu)}_2$ | 35 | 80 | 60:40 | 59/69 |


| | | | | | | |
|----|--|--|-----|----|-------|-------|
| 5 | $\text{Co(NTf}_2)_2$ | L₂-Pi(O<i>i</i>Bu)₂ | 35 | 79 | 50:50 | 53/61 |
| 6 | $\text{Co(ClO}_4)_2 \cdot 6\text{H}_2\text{O}$ | L₂-Pi(O<i>i</i>Bu)₂ | 35 | 69 | 58:42 | 47/50 |
| 7 | $\text{Co(BF}_4)_2 \cdot 6\text{H}_2\text{O}$ | L₂-Pi(O<i>i</i>Bu)₂ | 35 | 74 | 51:49 | 52/61 |
| 8 | Co(OTf)_2 | L₂-Pi(O<i>i</i>Bu)₂ | 20 | 69 | 42:58 | 62/80 |
| 9 | Co(OTf)_2 | L₂-Pi(O<i>i</i>Bu)₂ | 10 | 55 | 38:62 | 59/83 |
| 10 | Co(OTf)_2 | L₂-Pi(O<i>i</i>Bu)₂ | 0 | 27 | 36:64 | 50/86 |
| 11 | Co(OTf)_2 | L₂-Pi(O<i>i</i>Bu)₂ | -10 | 24 | 34:66 | 52/89 |
| 12 | Co(OTf)_2 | L₂-Pi(O<i>i</i>Pr)₂ | -10 | 53 | 25:75 | 60/80 |
| 13 | Co(OTf)_2 | L₂-Pi(OPh)₂ | -10 | 53 | 33:67 | 56/73 |
| 14 | Co(OTf)_2 | L₂-Pi(OBn)₂ | -10 | 52 | 20:80 | 71/89 |

^a Unless otherwise noted, the reactions were carried out with 2-(ethylthio)-3-methyl-1*H*-indole **2q** (0.15 mmol), diazo compound **1a** (0.1 mmol), metal salt/**ligand**(1:1, 10 mol%) in CHCl₃ (0.2 M). ^b Isolated yields of **3aq**. ^c The dr value was determined by ¹H NMR analysis. ^d Determined by HPLC on a chiral stationary phase. ^e DME = 1,2-dimethoxyethane.

6.2 Typical procedure for the asymmetric [3,3]-rearrangement




Procedure A: A dry reaction tube was charged with **L₂-Pi(O*i*Bu)₂** (7.6 mg, 10 mol%), Ni(OTf)₂ (3.6 mg, 10 mol%). Then CHCl₃ (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, thiindole **2** (0.12 mmol) was added successively at 35 °C. Then transfer the reaction tube to -20 °C, diazo compound **1** (0.10 mmol) was added finally. The reaction was detected by TLC. After the diazo compound **1** was fully consumed (detected by TLC), the residue was purified by column chromatography on silica gel to afford the product (Pet/EtOAc = 15/1 to Pet/EtOAc = 7/1 as eluent). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IF in comparison with the authentic racemates.




Procedure B: A dry reaction tube was charged with **L₂-Pi(O*i*Bu)₂** (7.6 mg, 10 mol%), Ni(OTf)₂ (3.6 mg, 10 mol%). Then CHCl₃ (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, thiindole **2** (0.12 mmol) was added successively at 35 °C. Then transfer the reaction tube to -20 °C, diazo compound **1** (0.10 mmol) was added finally. The reaction was detected by TLC. After the diazo compound **1** was fully consumed (detected by TLC), the residue was purified by column chromatography on silica gel to afford the product **3** (Pet/EtOAc = 15/1 to Pet/EtOAc = 7/1 as eluent). The product **3** was dissolved in 1.0 mL of CH₂Cl₂, *m*-CPBA (2.1 equiv) was added slowly. The reaction was stirred at room temperature for 30 min. To the mixture was added saturated aq. NaHCO₃ (3 mL) and the aqueous layer was separated and extracted with CH₂Cl₂ (3 mL × 2). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered and

concentrated. The residue was purified by column chromatography on silica gel to afford the product **4** (Pet/EtOAc = 7/1 to Pet/EtOAc = 4/1 as eluent). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IA, Daicel chiralcel IE, Daicel chiralcel IF in comparison with the authentic racemates.

Procedure C: A dry reaction tube was charged with **L₂-Pi(OiBu)₂** (7.6 mg, 10 mol%), Ni(NTf₂)₂ (6.2 mg, 10 mol%). Then CHCl₃ (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, thioindole **2** (0.12 mmol) was added successively at 35 °C. Then transfer the reaction tube to -20 °C, diazo compound **1** (0.10 mmol) was added finally. The reaction was detected by TLC. After the diazo compound **1** was fully consumed (detected by TLC), the residue was purified by column chromatography on silica gel to afford the product **3** (Pet/EtOAc = 15/1 to Pet/EtOAc = 7/1 as eluent). The product **3** was dissolved in 1.0 mL of CH₂Cl₂, *m*-CPBA (2.1 equiv) was added slowly. The reaction was stirred at room temperature for 30 min. To the mixture was added saturated aq. NaHCO₃ (3 mL) and the aqueous layer was separated and extracted with CH₂Cl₂ (3 mL × 2). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel to afford the product **4** (Pet/EtOAc = 7/1 to Pet/EtOAc = 4/1 as eluent). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IA, Daicel chiralcel IE, Daicel chiralcel IF in comparison with the authentic racemates.




Procedure D: A dry reaction tube was charged with **L₂-Pi(OiPr)₂** (7.0 mg, 10 mol%), Ni(OTf)₂ (3.6 mg, 10 mol%). Then CHCl₃ (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, thioindole **2** (0.12 mmol) was added successively at 35 °C. Then transfer the reaction tube to -20 °C, diazo compound **1** (0.10 mmol) was added finally. The reaction was detected by TLC. After the diazo compound **1** was fully consumed (detected by TLC), the residue was purified by column chromatography on silica gel to afford the product **3** (Pet/EtOAc = 15/1 to Pet/EtOAc = 7/1 as eluent). The product **3** was dissolved in 1.0 mL of CH₂Cl₂, *m*-CPBA (2.1 equiv) was added slowly. The reaction was stirred at room temperature for 30 min. To the mixture was added saturated aq. NaHCO₃ (3 mL) and the aqueous layer was separated and extracted with CH₂Cl₂ (3 mL × 2). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel to afford the product **4** (Pet/EtOAc = 7/1 to Pet/EtOAc = 4/1 as eluent). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IF in comparison with the authentic racemates.




Procedure E: A dry reaction tube was charged with **L₂-Pi(OBn)₂** (8.9 mg, 10 mol%), Co(OTf)₂ (3.6 mg, 10 mol%). Then CHCl₃ (0.5 mL) was added and the mixture was stirred at 35 °C for 30

minutes. Subsequently, thioindole **2q** (0.15 mmol) was added successively at 35 °C. Then transfer the reaction tube to –10 °C, diazo compound **1** (0.10 mmol) was added finally. The reaction was detected by TLC. After the diazo compound **1** was fully consumed (detected by TLC), the residue was purified by column chromatography on silica gel to afford the product **3** (Pet/EtOAc = 20/1 to Pet/EtOAc = 15/1 as eluent). The dr value was determined by ¹H NMR analysis and the enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IA in comparison with the authentic racemates.

6.3 General procedure for the preparation of the racemic products




Procedure F: A dry reaction tube was charged with *race*- L₂-PiPr₂ (6.3 mg, 10 mol%), Ni(OTf)₂ (3.6 mg, 10 mol%). Then CH₂Cl₂ (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, thioindole **2** (0.10 mmol) was added successively at 35 °C. Then transfer the reaction tube to 0 °C, diazo compound **1** (0.10 mmol) was added finally. The reaction was detected by TLC. After the diazo compound **1** was fully consumed (detected by TLC), the residue was purified by column chromatography on silica gel to afford the product **3** (Pet/EtOAc = 15/1 to Pet/EtOAc = 7/1 as eluent). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IF.



Procedure G: A dry reaction tube was charged with *race*- L₂-PiPr₂ (6.3 mg, 10 mol%), Ni(OTf)₂ (3.6 mg, 10 mol%). Then CH₂Cl₂ (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, thioindole **2** (0.10 mmol) was added successively at 35 °C. Then transfer the reaction tube to 0 °C, diazo compound **1** (0.10 mmol) was added finally. The reaction was detected by TLC. After the diazo compound **1** was fully consumed (detected by TLC), the residue was purified by column chromatography on silica gel to afford the product **3** (Pet/EtOAc = 15/1 to Pet/EtOAc = 7/1 as eluent). The product **3** was dissolved in 1.0 mL of CH₂Cl₂, *m*-CPBA (2.1 equiv) was added slowly. The reaction was stirred at room temperature for 30 min. To the mixture was added saturated aq. NaHCO₃ (3 mL) and the aqueous layer was separated and extracted with CH₂Cl₂ (3 mL × 2). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel to afford the product **4** (Pet/EtOAc = 7/1 to Pet/EtOAc = 4/1 as eluent). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IA, Daicel chiralcel IE, Daicel chiralcel IF.

6.4 Procedure for the gram-scale of asymmetric [3,3]-rearrangement



A 50 mL of dry round-bottom flask was charged with **L₂-Pi(O*i*Bu)₂** (226.5 mg, 10 mol%), Ni(OTf)₂ (106.8 mg, 10 mol%). Then CHCl₃ (15 mL) was added and the mixture was stirred at 35 °C for 10 hours. Subsequently, **2a** (586.8 mg, 3.60 mmol) was added successively at 35 °C. Then transfer the reaction flask to -20 °C, diazo compound **1a** (840.0 mg, 3.00 mmol) was added finally. After **1a** was fully consumed (40 hours), the residue was purified by column chromatography on silica gel to afford the product **3aa** as white solid (1.21 g, 96% yield). The product **3aa** was dissolved in 30 mL of CH₂Cl₂, *m*-CPBA (497.0 mg, 2.1 equiv) was added slowly. The reaction was stirred at room temperature for 30 min. To the mixture was added saturated aq. NaHCO₃ (30 mL) and the aqueous layer was separated and extracted with CH₂Cl₂. The combined organic extracts were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel to afford the product **4aa** as pale yellow solid (1.14 g, 85% yield, 97% ee).


7 The list of substrates scope

Table 7.1^a

| 1b-s | 2a | 3ba-3sa | 4ba-4sa |
|---|--|--|--|
| | | | |
| | | | |
| 4ba 74% yield, 93% ee (3ba: 84% yield, 48 h) | 4ca 63% yield, 91% ee (3ca: 84% yield, 48 h) | 4da 82% yield, 92% ee (3da: 91% yield, 28 h) | 4ea 82% yield, 93% ee (3ea: 97% yield, 3 d) |
| | | | |
| 4ga ^b 92% yield, 95% ee (3ga: 99% yield, 21 h) | 4ha 89% yield, 94% ee (3ha: 99% yield, 18 h) | 4ia 76% yield, 93% ee (3ia: 86% yield, 28 h) | 4ka 51% yield, 95% ee (3ka: 91% yield, 29 h) |
| | | | |
| 4ma ^b 84% yield, 94% ee (3ma: 98% yield, 21 h) | 4na 86% yield, 91% ee (3na: 99% yield, 18 h) | 4o 68% yield, 92% ee (3oa: 99% yield, 24 h) | 4qa 70% yield, 94% ee (3qa: 99% yield, 24 h) |
| | | | |
| | | | 4ua 5% yield, 78% ee (3ua: 23% yield, 24 h) |
| 4aa 39% yield, 82% ee (3aa: 75% yield, 39 h) | 4ba 30% yield, 82% ee (3ba: 75% yield, 39 h) | | |

^a Unless otherwise noted, the initial reactions were carried out with **1** (0.10 mmol), **2a** (1.2 equiv), Ni(OTf)₂/**L₂-Pi(OBu)₂** (1:1, 10 mol%) in CHCl₃ (0.2 M) at -20 °C. Isolated yield of **3** and isolated yield of **4** after two steps. The ee value of **4** was determined by HPLC analysis on a chiral stationary phase. ^b Ni(NTf)₂ was used instead of Ni(OTf)₂.


Table 7.2^a



^a Unless otherwise noted, the initial reactions were carried out with **1a** (0.10 mmol), **2** (1.2 equiv), Ni(OTf)₂/**L₂-Pi(OBu)₂** (1:1, 10 mol%) in CHCl₃ (0.2 M) at -20 °C. Isolated yield of **3** and isolated yield of **4** after two steps. The ee value of **4** was determined by HPLC analysis on a chiral stationary phase. ^b Ni(NTf)₂ was used instead of Ni(OTf)₂. ^c **L₂-Pi(OiPr)₂** was used instead of **L₂-Pi(OBu)₂**. ^d The reaction was carried out with **1a** (0.10 mmol), **2q** (1.5 equiv), Co(OTf)₂/**L₂-Pi(OBn)₂** (1:1, 10 mol%) in CHCl₃ (0.2 M) at -10 °C. Isolated yield of **3aq**. The dr value was determined by ¹H NMR analysis and the ee value was for the major diastereoisomer.

8 Procedure for the transformation of product **3aa** and **4aa**

8.1 Transformation of product **4aa**



8.1.1 Reduction of 4aa to 5aa

A dry tube was charged with 10% Pd/C (8.9 mg), **4aa** (0.20 mmol, 89.4 mg), then, MeOH (1.0 mL) was added. The mixture was stirred at room temperature for 24 h under an H₂ atmosphere. The reaction mixture was filtered with a pad of celite and the filtrate was concentrated in vacuo, the residue was purified by column chromatography on silica gel to afford the corresponding product **5aa** (Pet/EtOAc = 7/1 to Pet/EtOAc = 4/1 as eluent) as white solid (78.1 mg, 87% yield). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IC, in comparison with the authentic racemates.

8.1.2 Direct amidation with *L*-leucine methyl ester hydrochloride

According to literature report⁹, *L*-leucin methyl ester hydrochlorid (18.2 mg, 2.0 equiv), toluene (0.5 mL), and Et₃N (13 μ L, 2.0 equiv) was added into a reaction tube equipped with a stirring bar. After stirred at room temperature for 10 min, **5aa** (22.5 mg, 0.05 mmol), 1-hydroxybenzotriazole (14 mg, 2.0 equiv), and toluene (0.5 mL) was added continuously. Then the tube was sealed and heated at 45 °C for 5 days. The mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography to give product **6aa** ((Pet/EtOAc = 4/1 to Pet/EtOAc = 2/1 as eluent) as white solid (19.4 mg, 80% yield). The diastereoselectivity was determined by ¹H NMR analysis.

8.1.3 Esterification

According to literature report⁹, **5aa** (22.5 mg, 0.05 mmol), MeOH (0.4 mL) and THF (0.1 mL), LiCl (10.6 mg, 5.0 equiv), and Et₃N (34 μ L, 5.0 equiv) was added in sequence to a dry tube equipped with a stirring bar. After stirred at 35 °C for 24 hours, the mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography to give product **7aa** ((Pet/EtOAc = 7/1 to Pet/EtOAc = 4/1 as eluent) as white solid (17.6 mg, 95% yield). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IE, in comparison with the authentic racemates.

8.1.4 Reduction to alcohol


According to literature report¹⁰, to a solution of **5aa** (64.2 mg, 0.14 mmol) in MeOH (1.0 mL) was added NaBH₄ (42.3 mg, 8.0 equiv) at 0 °C and the mixture was stirred overnight at room temperature. After quenching with 1.0 M HCl, the resultant mixture was extracted with EtOAc. The combined organic layer was washed with brine and dried over Na₂SO₄. After evaporation of the organic solvent under reduced pressure, the crude mixture was purified by silica gel column chromatography to give

product **8aa** ((Pet/EtOAc = 4/1 to Pet/EtOAc = 1/1 as eluent) as white solid (47.1 mg, 96% yield). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IC, in comparison with the authentic racemates.

8.2 Transformation of product **3aa** to chiral sulfoxide **9aa**


The sulfoxide were synthesized according to our previous work⁹.

8.2.1 Procedure for the preparation of the racemic sulfoxide **9aa**



A dry reaction tube was charged with racemic **L₂-PiPr₂** (3.2 mg, 10 mol%), Fe(OTf)₃ (2.5 mg, 10 mol%). Then THF (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, racemic sulfide **3aa** (20.7 mg, 0.05 mmol) was added successively at 35 °C. Transfer the reaction tube to -20 °C, then 10% H₂O₂ (25 μL, 5.0 equiv) was added finally. The reaction was detected by TLC. The reaction mixture was diluted by 2 ml H₂O, and extracted by EtOAc. The organic phase was passed through anhydrous Na₂SO₄. After removal of the solvent under reduced pressure, the residue was purified by column chromatography on silica gel to afford the corresponding racemic sulfoxide **9aa** (Pet/EtOAc = 4/1 to Pet/EtOAc = 1/2 as eluent) as white solid (8.6 mg, 40% yield).

8.2.2 Procedure for the preparation of the chiral sulfoxide **9aa**




A dry reaction tube was charged with **L₃-PiPr₂Ad** (5.5 mg, 12 mol%), Fe(OTf)₃ (2.5 mg, 10 mol%). Then THF (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, sulfide **3aa** (20.7 mg, 0.05 mmol) was added successively at 35 °C. Then transfer the reaction tube to -20 °C, then 10% H₂O₂ (25 μL, 5.0 equiv) was added finally. The reaction was detected by TLC. The reaction mixture was diluted by 2 ml H₂O, and extracted by EtOAc. The organic phase was passed through anhydrous Na₂SO₄. After removal of the solvent under reduced pressure, the residue was purified by column chromatography on silica gel to afford the corresponding sulfoxide **9aa** (Pet/EtOAc = 4/1 to Pet/EtOAc = 1/2 as eluent) as white solid (10.8 mg, 50% yield). The dr value


was determined by ^1H NMR analysis and the enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel ID in comparison with the authentic racemates.

9 Control experiments and mechanistic studies

To verify the proton transfer process in this reaction, the 1-methyl-2-(methylthio)-1*H*-indole **2r** was subjected to the standard conditions, but the reaction resulted in a mixture with a large residue of the substrates, and **3ar** was not detected (eq. 1). It suggested the significant role of the N-H unit in forming the key sulfonium ylide intermediate through proton transfer. Furthermore, the *N*-deuterium-labeled indole **2a** was used to probe into the proton shift process (eq. 2). We carried out the experiments in dry solvent without additional water, and only minor deuterium labeled product was obtained. When trace amount of H_2O (around 1.5 equiv) was added, the product was found nearly non-deuterium. However, the *d*-**3aa** product was found to be the major one if D_2O was used instead. When non-deuterium **2a** with D_2O were used in the reaction, the *d*-**3aa** product was also detected. The results indicated the trace amount of water in the system might be in charge of proton-transfer.



9.1 The enantioselective thio-Claisen rearrangement reaction of α -diazo pyrazoleamides **1a** and 2-(ethylthio)-1-methyl-1*H*-indole **2r**




Procedure: A dry reaction tube was charged with L₂-Pi(O*i*Bu)₂ (7.6 mg, 10 mol%), Ni(OTf)₂ (3.6 mg, 10 mol%), then CHCl₃ (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, 2-(methylthio)-1*H*-indole **2r** (0.12 mmol, 1.2 equiv) was added successively at 35 °C.





Then transfer the reaction tube to -20°C , diazo compound **1a** (0.10 mmol) was added finally. The reaction was stirred at -20°C and detected by TLC. The desired product **3ar** could not be detected.


9.2 Deuterium labeled experiments

To gain insight into the mechanism of the asymmetric thio-Claisen rearrangement reaction, the deuterium-labeled experiments were performed according to the equations shown below. After distilled from CaH_2 , the solvent CH_2Cl_2 was treated without water or oxygen and dried over 4 Å MS, which was activated at 600°C for 1 hour before use. All the substrates and reaction solvent were added to the reaction tube in the glove box under an N_2 atmosphere at room temperature.


Procedure: A dry reaction tube was charged with $\text{L}_2\text{-Pi(OiBu)}_2$ (7.6 mg, 10 mol%) and $\text{Ni}(\text{OTf})_2$ (3.6 mg, 10 mol%) in the glove box under an N_2 atmosphere. Then CH_2Cl_2 (0.5 mL) was added and the mixture was stirred at room temperature for 30 minutes. Subsequently, 2-(methylthio)-1*H*-indole **2a-d** (0.12 mmol, 1.2 equiv) and diazo compound **1a** (0.10 mmol) was added successively. Then transfer the reaction tube to -20°C , the additive (around 1.5 equiv) was added finally. After the diazo compound **1a** was fully consumed (detected by TLC), the residue was purified by column chromatography on silica gel to afford the product. The deuterium-laballed ratios the products were detected by ^1H NMR.








9.3 The enantioselective thiophenyl Claisen rearrangement reaction of (*Z/E*)-2-diazo-4-phenyl-1-(3,4,5-trimethyl-1*H*pyrazol-1-yl)but-3-en-1-one and 2-(methylthio)-1*H*-indole 2a



Procedure: A dry reaction tube was charged with **L₂-Pi(O*i*Bu)₂** (7.6 mg, 10 mol%), **Ni(OTf)₂** (3.6 mg, 10 mol%), then **CHCl₃** (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, 2-(methylthio)-1*H*-indole **2a** (0.12 mmol, 1.2 equiv) was added successively at 35 °C. Then transfer the reaction tube to -20 °C, diazo compound **1a** (0.10 mmol, *Z/E* = 1.77/1) was added finally. The reaction was stirred at -20 °C and detected by TLC. The desired product **3aa** was obtained in 86% yield with 93% ee. The enantioselectivity (ee) of product **3aa** was determined by high performance liquid chromatography (HPLC) with chiralcel IF in comparison with the authentic racemates.

9.4 Proposed catalytic model



10 X-ray crystal structure




Figure S1. X-ray Crystal Structure of product **4da**

The crystal of product **4da** was obtained in the solvents of THF and n-hexane. CCDC 1974972 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via <https://www.ccdc.cam.ac.uk/>.





Figure S2. X-ray Crystal Structure of chiral sulfoxide **9da**

The crystal of product **4da** was obtained in the solvents of THF, Et₂O and n-hexane. CCDC 1998226 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via <https://www.ccdc.cam.ac.uk/>.

Note: The chiral sulfoxide **9da** could be obtained through the following procedure.



Step 1: A dry reaction tube was charged with **L₂-Pi(O*i*Bu)₂** (7.6 mg, 10 mol%), **Ni(OTf)₂** (3.6 mg, 10 mol%). Then **CHCl₃** (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, sulfide **2a** (0.12 mmol) was added successively at 35 °C. Then transfer the reaction tube to -20 °C, diazo compound **1d** (0.10 mmol) was added finally. The reaction was detected by TLC. After the diazo compound **1d** was fully consumed (detected by TLC), the residue was purified by column chromatography on silica gel to afford the product **3da** as white solid (38.3 mg, 89% yield). The enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IF in comparison with the authentic racemates.

Step 2: A dry reaction tube was charged with **L₃-PiPr₂Ad** (12 mol%), **Fe(OTf)₃** (10 mol%). Then **THF** (0.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, sulfide **3da** (38 mg, 0.088 mmol) was added successively at 35 °C. Then transfer the reaction tube to -20 °C, then 10% **H₂O₂** (5.0 equiv) was added finally. The reaction was detected by TLC. The reaction mixture was diluted by 2 ml **H₂O**, and extracted by **EtOAc**. The organic phase was passed through anhydrous **Na₂SO₄**. After removal of the solvent under reduced pressure, the residue was purified by column chromatography on silica gel to afford the corresponding sulfoxide **9da** as white solid (33.1 mg, 84% yield). The dr value was determined by ¹H NMR analysis and the enantiomeric excess (ee) was determined by high-performance liquid chromatography (HPLC) with Daicel chiralcel IB in comparison with the authentic racemates.





Figure S3. X-ray Crystal Structure of the chiral nickel(II) complex

The crystal of **L₂-Pi(O*i*Bu)₂/Ni(BF₄)₂·6H₂O** complex was obtained in the solvents of THF and *n*-hexane. CCDC 1948996 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via <https://www.ccdc.cam.ac.uk/>.

11 Spectral characterization data and HPLC conditions for the products

(*R,E*)-4-(2-(methylthio)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (3aa)



Following the typical procedure A.


39.1 mg, 94% yield; white solid; M.p. 49–52 °C. R_f = 0.3 (Pet/EtOAc = 10/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 98/2, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (minor) = 39.490 min, t (major) = 42.727 min. ee = 96%. $[\alpha]^{22}_D$ = +24.2 (*c* = 0.48, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.23 (s, 1H), 7.87 (dd, *J* = 15.2, 8.4 Hz, 1H), 7.48 – 7.44 (m, 1H), 7.36 (d, *J* = 8.4 Hz, 1H), 7.31 – 7.23 (m, 5H), 7.20 – 7.11 (m, 2H), 7.00 – 6.96 (m, 1H), 5.59 (d, *J* = 8.8 Hz, 1H), 2.48 (s, 3H), 2.28 (s, 3H), 2.16 (s, 3H), 1.89 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 165.1, 152.1, 150.4, 141.7, 139.8, 136.7, 128.4, 128.0, 127.8, 126.5, 126.4, 122.9, 122.3, 120.5, 120.4, 119.9, 117.7, 110.8, 45.5, 20.2, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₂₅H₂₆N₃OS⁺ ([M + H]⁺) = 416.1791, found 416.1786.

IR (neat): 1692, 1633, 1491, 1427, 1381, 1353, 1008, 742, 702 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 39.557 | 7723154 | 50.09 |
| 2 | 43.491 | 7693910 | 49.91 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 39.490 | 481744 | 2.02 |
| 2 | 42.727 | 23361773 | 97.98 |

(*R,E*)-4-(2-(methylthio)-1*H*-indol-3-yl)-4-(o-tolyl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (3da)





Following the typical procedure A.
 38.3 mg, 89% yield; white solid; M.p. 163–167 °C. $R_f = 0.3$ (Pet/EtOAc = 10/1).
 Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 98/2, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (minor) = 30.931 min, t (major) = 42.863 min. ee = 94%. $[\alpha]^{21}_D = +34.9$ ($c = 0.76$, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.27 (s, 1H), 7.83 (dd, $J = 15.6, 7.6$ Hz, 1H), 7.43 – 7.36 (m, 2H), 7.31 – 7.24 (m, 2H), 7.16 – 7.08 (m, 4H), 6.98 – 6.94 (m, 1H), 5.64 – 5.62 (m, 1H), 2.49 (s, 3H), 2.28 (s, 3H), 2.19 (s, 3H), 2.12 (s, 3H), 1.88 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 165.3, 152.1, 151.2, 140.0, 139.7, 136.54, 136.50, 130.5, 128.3, 127.7, 127.1, 126.7, 125.9, 122.7, 121.7, 120.1, 119.8, 119.7, 117.6, 110.7, 43.2, 19.8, 19.6, 12.8, 12.3, 7.7.

ESI-HRMS: calcd for C₂₆H₂₈N₃OS⁺ ([M + H]⁺) = 430.1948, found 430.1943.

IR (neat): 2923, 1683, 1631, 1426, 1008, 939, 740 cm⁻¹.



(*R,E*)-4-(2-(ethylthio)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (3ab)



Following the typical procedure A.
 37.3 mg, 87% yield; white solid; M.p. 50–55 °C. $R_f = 0.3$ (Pet/EtOAc = 10/1).
 Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 98/2, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (minor) = 32.048 min, t (major) = 36.759 min. ee = 92%. $[\alpha]^{22}_D = +20.0$ ($c = 0.60$, in CH₂Cl₂).


¹H NMR (400 MHz, Chloroform-*d*) δ 8.19 (s, 1H), 7.84 (dd, $J = 15.6, 8.4$ Hz, 1H), 7.47 – 7.43 (m,

1H), 7.37 (d, J = 8.0 Hz, 1H), 7.31 – 7.23 (m, 5H), 7.21 – 7.13 (m, 2H), 7.00 – 6.96 (m, 1H), 5.60 (d, J = 8.4 Hz, 1H), 2.71 (q, J = 7.2 Hz, 2H), 2.48 (s, 3H), 2.16 (s, 3H), 1.89 (s, 3H), 1.18 (t, J = 7.3 Hz, 3H).


$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 165.1, 152.1, 150.3, 141.7, 136.7, 128.3, 128.0, 126.4, 126.3, 122.9, 122.4, 121.3, 120.5, 119.7, 117.7, 110.7, 45.5, 31.1, 15.4, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for $\text{C}_{26}\text{H}_{28}\text{N}_3\text{OS}^+$ ($[\text{M} + \text{H}]^+$) = 430.1948, found 430.1946.

IR (neat): 1687, 1633, 1491, 1445, 1380, 1353, 1284, 1008, 939, 742, 701 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 32.691 | 17808082 | 49.44 |
| 2 | 36.604 | 18208111 | 50.56 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 32.048 | 1180800 | 3.92 |
| 2 | 36.759 | 28942559 | 96.08 |

(*R,E*)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4aa)



Following the typical procedure B.


38.9 mg, 87% yield; white solid; M.p. 105–110 °C. R_f = 0.2 (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 24.292 min, t (minor) = 29.860 min. ee = 96%. $[\alpha]^{17}\text{D}$ = +81.4 (c = 0.69, in CH₂Cl₂).

^1H NMR (400 MHz, Chloroform-*d*) δ 9.33 (s, 1H), 7.78 (dd, J = 15.6, 8.0 Hz, 1H), 7.50 – 7.42 (m, 3H), 7.32– 7.26 (m, 4H), 7.26 – 7.19 (m, 2H), 7.06 – 7.02 (m, 1H), 6.01 (d, J = 8.0 Hz, 1H), 3.04 (s, 3H), 2.47 (s, 3H), 2.13 (s, 3H), 1.88 (s, 3H).


$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.4, 148.4, 140.4, 139.7, 136.0, 129.2, 128.6, 128.0, 126.9, 126.2, 126.0, 123.7, 122.8, 121.4, 121.3, 118.0, 112.5, 45.4, 43.6, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{26}\text{N}_3\text{O}_3\text{S}^+$ ($[\text{M} + \text{H}]^+$) = 448.1689, found 448.1693.

IR (neat): 1696, 1635, 1381, 1353, 1310, 1187, 1143, 1089, 1007, 958, 70, 701, 523, 432 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 24.577 | 17498224 | 49.64 |
| 2 | 30.055 | 17750350 | 50.36 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 24.292 | 11578376 | 98.01 |
| 2 | 29.860 | 234710 | 1.99 |

(R,E)-4-(2-fluorophenyl)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ba)



Following the typical procedure B.

34.2 mg, 74% yield; white solid; M.p. 102–106 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 27.239 min, t (minor) = 37.359 min. ee = 93%. $[\alpha]^{22}_D = +69.0$ ($c = 0.62$, in CH_2Cl_2). 7


^1H NMR (400 MHz, Chloroform-*d*) δ 9.30 (s, 1H), 7.77 (dd, $J = 15.6, 7.6$ Hz, 1H), 7.54 – 7.52 (m, 1H), 7.47 – 7.38 (m, 3H), 7.33 – 7.29 (m, 1H), 7.26 – 7.21 (m, 1H), 7.14 – 6.97 (m, 3H), 6.19 (d, $J = 7.6$ Hz, 1H), 3.08 (s, 3H), 2.47 (s, 3H), 2.11 (s, 3H), 1.88 (s, 3H).

$^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 164.8, 160.7 (d, $J = 246.2$ Hz), 152.4, 147.3, 139.7, 135.8, 129.7 (d, $J = 3.7$ Hz), 129.1 (d, $J = 8.4$ Hz), 128.8, 127.8 (d, $J = 13.6$ Hz), 126.3, 126.1, 124.2 (d, $J = 3.5$ Hz), 123.6, 122.3, 121.5, 120.2, 117.9, 115.8 (d, $J = 21.6$ Hz), 112.6, 45.2, 38.2, 12.7, 12.3, 7.7.

$^{19}\text{F}\{^1\text{H}\}$ NMR (376 MHz, CDCl_3) δ -114.53.


ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3\text{FS}^+ ([\text{M} + \text{H}]^+) = 466.1595$, found 466.1595.

IR (neat): 1705, 1695, 1380, 1353, 1339, 1139, 914, 752, 524 cm^{-1} .




| | Retention Time | Area | % Area |
|--|----------------|------|--------|
|--|----------------|------|--------|

| | | | |
|---|--------|---------|-------|
| 1 | 27.703 | 2778541 | 49.83 |
| 2 | 37.252 | 2797254 | 50.17 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 27.239 | 31694850 | 96.59 |
| 2 | 37.359 | 1117628 | 3.41 |

(S,E)-4-(2-chlorophenyl)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ca)



Following the typical procedure B.


30.4 mg, 63% yield; white solid; M.p. 118–123 °C. R_f = 0.2 (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 26.044 min, t (minor) = 37.556 min. ee = 91%. [α]²²_D = -16.0 (c = 0.52, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.36 (s, 1H), 7.70 (dd, *J* = 15.6, 7.2 Hz, 1H), 7.52 – 7.50 (m, 1H), 7.45 – 7.39 (m, 2H), 7.38 – 7.28 (m, 3H), 7.24 – 7.18 (m, 2H), 7.08 – 7.04 (m, 1H), 6.26 (dd, *J* = 7.2, 1.6 Hz, 1H), 2.90 (s, 3H), 2.46 (s, 3H), 2.10 (s, 3H), 1.86 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.5, 147.9, 139.7, 138.1, 135.7, 134.4, 130.1, 130.1, 129.1, 128.7, 127.0, 126.9, 126.1, 123.6, 122.3, 121.6, 120.0, 117.9, 112.6, 44.8, 41.8, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₂₅H₂₅N₃O₃³⁵ClS⁺ ([M + H]⁺) = 482.1300, found 482.1304. C₂₅H₂₅N₃O₃³⁷ClS⁺ ([M + H]⁺) = 484.1270, found 484.1277.

IR (neat): 1695, 1635, 1380, 1352, 1315, 1189, 1137, 1004, 958, 940, 745, 524, 503, 431 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 26.128 | 15525662 | 49.81 |
| 2 | 37.028 | 15642912 | 50.19 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 26.044 | 27945125 | 95.28 |
| 2 | 37.556 | 1383496 | 4.72 |

(R,E)-4-(2-(methylsulfonyl)-1H-indol-3-yl)-4-(o-tolyl)-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-2-en-1-one (4da)



Following the typical procedure B.


37.8 mg, 82% yield; white solid; M.p. 174–180 °C. $R_f = 0.3$ (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 17.638 min, t (minor) = 24.729 min. ee = 92%. $[\alpha]^{19}_D = +11.5$ ($c = 0.75$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.24 (s, 1H), 7.76 (dd, $J = 15.6, 6.8$ Hz, 1H), 7.51 (d, $J = 8.4$ Hz, 1H), 7.45 (d, $J = 8.4$ Hz, 1H), 7.35 – 7.23 (m, 3H), 7.19 – 7.12 (m, 3H), 7.08 – 7.04 (m, 1H), 6.13 (dd, $J = 7.2, 1.6$ Hz, 1H), 2.81 (s, 3H), 2.49 (s, 3H), 2.29 (s, 3H), 2.12 (s, 3H), 1.89 (s, 3H).


$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.9, 152.39, 149.29, 139.7, 138.8, 137.3, 135.7, 130.9, 128.5, 128.3, 127.3, 127.0, 126.1, 123.1, 122.7, 121.5, 121.2, 117.9, 112.4, 44.6, 41.5, 19.7, 19.7, 12.7, 12.3, 7.6.

ESI-HRMS: calcd for $\text{C}_{26}\text{H}_{28}\text{N}_3\text{O}_3\text{S}^+$ ($[\text{M} + \text{H}]^+$) = 462.1846, found 462.1850.

IR (neat): 2361, 2310, 1681, 1624, 1385, 1356, 1314, 1274, 1138, 758, 747 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 17.445 | 9799732 | 49.73 |
| 2 | 23.724 | 9907150 | 50.27 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 17.638 | 24956247 | 95.94 |
| 2 | 24.729 | 1056782 | 4.06 |

(R,E)-4-(3-fluorophenyl)-4-(2-(methylsulfonyl)-1H-indol-3-yl)-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-2-en-1-one (4ea)



Following the typical procedure B.

38.2 mg, 82% yield; white solid; M.p. 104–107 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 18.978 min, t (minor) = 21.770 min. ee = 93%. $[\alpha]^{18}_D = +82.8$ ($c = 0.69$, in CH_2Cl_2).


¹H NMR (400 MHz, Chloroform-*d*) δ 9.38 (s, 1H), 7.71 (dd, *J* = 15.2, 8.4 Hz, 1H), 7.51 – 7.43 (m, 2H), 7.41 – 7.39 (m, 1H), 7.33 – 7.29 (m, 1H), 7.24 – 7.20 (m, 1H), 7.10 – 7.03 (m, 2H), 7.02 – 6.98 (m, 1H), 6.93 – 6.89 (m, 1H), 6.00 (d, *J* = 8.4 Hz, 1H), 3.09 (s, 3H), 2.47 (s, 3H), 2.13 (s, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.6, 162.9 (d, *J* = 245.0 Hz), 152.6, 147.3, 142.9 (d, *J* = 6.8 Hz), 139.7, 136.0, 130.1 (d, *J* = 8.2 Hz), 129.3, 126.3, 125.7, 124.2, 123.7 (d, *J* = 2.9 Hz), 122.6, 121.6, 120.6, 118.1, 115.0 (d, *J* = 22.2 Hz), 113.9 (d, *J* = 20.9 Hz), 112.6, 45.6, 43.2 (d, *J* = 1.8 Hz), 12.7, 12.3, 7.7.


¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ -112.39.

ESI-HRMS: calcd for C₂₅H₂₅N₃O₃FS⁺ ([M + H]⁺) = 466.1595, found 466.1591.

IR (neat): 1696, 1381, 1353, 1312, 1136, 1007, 957, 937, 747, 523, 432 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 18.374 | 2050728 | 50.63 |
| 2 | 21.010 | 1999398 | 49.37 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 18.978 | 15326409 | 96.67 |
| 2 | 21.770 | 527544 | 3.33 |

(*R,E*)-4-(3-chlorophenyl)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4fa)



Following the typical procedure B.

39.0 mg, 81% yield; white solid; M.p. 111–115 °C. R_f = 0.2 (Pet/EtOAc = 4/1).

Dissolved in isopropanol for HPLC; **HPLC** (Chiracel IF column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 18.162 min, t (minor) = 20.999 min. ee = 93%. [α]¹⁹D = +88.0 (*c* = 0.75, in CH₂Cl₂).


¹H NMR (400 MHz, Chloroform-*d*) δ 9.41 (s, 1H), 7.72 (dd, *J* = 15.6, 8.4 Hz, 1H), 7.53 – 7.45 (m, 2H), 7.42 – 7.40 (m, 1H), 7.35 – 7.30 (m, 2H), 7.22 – 7.18 (m, 3H), 7.10 – 7.05 (m, 1H), 6.01 (d, *J* = 8.4, 1H), 3.11 (s, 3H), 2.49 (s, 3H), 2.15 (s, 3H), 1.90 (s, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.6, 152.6, 147.2, 142.5, 139.7, 136.0, 134.5, 129.8, 129.3, 128.0, 127.2, 126.3, 126.2, 125.7, 124.2, 122.5, 121.6, 120.5, 118.1, 112.7, 45.6, 43.2, 12.7,


12.3, 7.7.

ESI-HRMS: calcd for $C_{25}H_{25}N_3O_3^{35}ClS^+$ ($[M + H]^+$) = 482.1300, found 482.1304. $C_{25}H_{25}N_3O_3^{37}ClS^+$ ($[M + H]^+$) = 484.1270, found 484.1275.

IR (neat): 1696, 1636, 1426, 1381, 1353, 1312, 1187, 1144, 1087, 1006, 959, 831, 787, 744, 682, 523 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 19.042 | 3165185 | 50.21 |
| 2 | 21.631 | 3138827 | 49.79 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 18.162 | 12103848 | 96.58 |
| 2 | 20.999 | 428117 | 3.42 |

(*R,E*)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-4-(m-tolyl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ga)



Following the typical procedure C.


42.6 mg, 92% yield; white solid; M.p. 94–100 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 18.350 min, t (minor) = 21.557 min. ee = 95%. $[\alpha]^{18}_D = +80.9$ ($c = 0.47$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.16 (s, 1H), 7.78 (dd, $J = 15.6, 8.4$ Hz, 1H), 7.50 – 7.42 (m, 3H), 7.34 – 7.30 (m, 1H), 7.18 – 7.13 (m, 2H), 7.11 – 7.02 (m, 3H), 5.98 (d, $J = 8.4$ Hz, 1H), 3.07 (s, 3H), 2.49 (s, 3H), 2.28 (s, 3H), 2.15 (s, 3H), 1.89 (s, 3H).


$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.8, 152.4, 148.5, 140.3, 139.7, 138.2, 136.0, 129.3, 128.7, 128.4, 127.7, 126.2, 126.1, 125.0, 123.6, 122.9, 121.5, 121.4, 117.9, 112.5, 45.5, 43.6, 21.5, 12.7, 12.3, 7.6.

ESI-HRMS: calcd for $C_{26}H_{28}N_3O_3S^+$ ($[M + H]^+$) = 462.1846, found 462.1850.

IR (neat): 1696, 1636, 1380, 1352, 1311, 1128, 1142, 1089, 1007, 958, 750, 702, 523, 433 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 18.548 | 11782411 | 50.61 |
| 2 | 21.484 | 11497594 | 49.39 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 18.350 | 37298051 | 97.54 |
| 2 | 21.557 | 939831 | 2.46 |

(R,E)-4-(4-fluorophenyl)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ha)



Following the typical procedure B.

41.5 mg, 89% yield; white solid; M.p. 100–105 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 16.412 min, t (minor) = 21.238 min. ee = 94%. $[\alpha]^{26}_D = +68.7$ ($c = 0.67$, in CH_2Cl_2).


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.36 (s, 1H), 7.73 (dd, $J = 15.6, 8.4$ Hz, 1H), 7.50 – 7.39 (m, 3H), 7.35 – 7.25 (m, 3H), 7.08 – 7.04 (m, 1H), 7.00 – 6.91 (m, 2H), 5.99 (d, $J = 8.4$ Hz, 1H), 3.09 (s, 3H), 2.48 (s, 3H), 2.15 (s, 3H).

$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.7, 161.7 (d, $J = 244.3$ Hz), 152.5, 148.0, 139.7, 136.1 (d, $J = 3.4$ Hz), 136.0, 129.6 (d, $J = 7.9$ Hz), 129.3, 126.3, 125.8, 123.9, 122.7, 121.5, 121.1, 118.0, 115.4 (d, $J = 21.2$ Hz), 112.6, 45.5, 42.9, 12.6, 12.3, 7.6.

$^{19}\text{F}\{^1\text{H}\} \text{NMR}$ (376 MHz, CDCl_3) δ -115.68.


ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3\text{FS}^+ ([\text{M} + \text{H}]^+) = 466.1595$, found 466.1606.

IR (neat): 1697, 1636, 1505, 1381, 1353, 1312, 1224, 1144, 1090, 1008, 959, 824, 746, 523 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 16.412 | 466.1595 | 94.00 |
| 2 | 21.238 | 466.1606 | 6.00 |

| | | | |
|---|--------|---------|-------|
| 1 | 16.482 | 7595627 | 51.12 |
| 2 | 21.121 | 7262678 | 48.88 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 16.412 | 16041092 | 96.87 |
| 2 | 21.238 | 518703 | 3.13 |

(R,E)-4-(4-chlorophenyl)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ia)



Following the typical procedure B.


36.6 mg, 76% yield; white solid; M.p. 114–120 °C. R_f=0.2 (Pet/EtOAc=4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 21.546 min, t (minor) = 27.640 min. ee = 93%. [α]¹⁹_D = +67.5 (c = 0.73, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.35 (s, 1H), 7.72 (dd, *J* = 15.6, 8.4 Hz, 1H), 7.50 – 7.44 (m, 2H), 7.41 – 7.39 (m, 1H), 7.35 – 7.31 (m, 1H), 7.26 – 7.24 (m, 4H), 7.09 – 7.04 (m, 1H), 5.98 (dd, *J* = 8.4, 1.2 Hz, 1H), 3.10 (s, 3H), 2.48 (s, 3H), 2.15 (s, 3H), 1.90 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.6, 152.6, 147.5, 139.7, 138.9, 136.0, 132.8, 129.3, 129.3, 128.7, 126.3, 125.7, 124.1, 122.6, 121.6, 120.7, 118.1, 112.6, 45.6, 42.9, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₂₅H₂₅N₃O₃³⁵ClS⁺ ([M + H]⁺) = 482.1300, found 482.1305. C₂₅H₂₅N₃O₃³⁷ClS⁺ ([M + H]⁺) = 484.1270, found 482.1274.

IR (neat): 1696, 1636, 1489, 1380, 1353, 1311, 1279, 1186, 1144, 1090, 1008, 958, 940, 818, 750, 522 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 21.744 | 4368813 | 49.96 |
| 2 | 27.544 | 4375791 | 50.04 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 21.546 | 25231568 | 96.34 |
| 2 | 27.640 | 959913 | 3.66 |

(R,E)-4-(4-bromophenyl)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ja)



Following the typical procedure B.

43.1 mg, 82% yield; white solid; M.p. 125–130 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IA** column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 11.039 min, t (minor) = 14.767 min. ee = 92%. $[\alpha]^{24}_D = +55.8$ ($c = 0.76$, in CH_2Cl_2).


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.36 (s, 1H), 7.71 (dd, $J = 15.6, 8.4$ Hz, 1H), 7.51 – 7.38 (m, 5H), 7.35 – 7.30 (m, 1H), 7.20 – 7.18 (m, 2H), 7.10 – 7.03 (m, 1H), 5.97 (d, $J = 8.4$ Hz, 1H), 3.11 (s, 3H), 2.48 (s, 3H), 2.15 (s, 3H).

$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.6, 152.6, 147.4, 139.7, 139.5, 136.1, 131.7, 129.7, 129.4, 126.4, 125.7, 124.2, 122.6, 121.6, 121.0, 120.7, 118.1, 112.7, 45.6, 43.0, 12.6, 12.3, 7.6.


ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3^{79}\text{BrS}^+$ ($[\text{M} + \text{H}]^+$) = 526.0795, found 526.0801.

$\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3^{81}\text{BrS}^+([\text{M} + \text{H}]^+) = 528.0774$, found 528.0780.

IR (neat): 2361, 2354, 1696, 1636, 1380, 1353, 1310, 1144, 1007, 959 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 11.035 | 9003009 | 50.37 |
| 2 | 14.979 | 8869137 | 49.63 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 11.039 | 997561 | 3.86 |
| 2 | 14.767 | 24839138 | 96.14 |

(R,E)-4-(4-iodophenyl)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ka)

Following the typical procedure B.



29.5 mg, 51% yield; pale yellow solid; M.p. 130–136 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 25.110 min, t (minor) = 32.542 min. ee = 95%. $[\alpha]^{23}_D = +47.3$ ($c = 0.64$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.29 (s, 1H), 7.70 (dd, $J = 15.6, 8.4$ Hz, 1H), 7.62 – 7.57 (m, 2H), 7.50 – 7.40 (m, 3H), 7.35 – 7.31 (m, 1H), 7.10 – 7.05 (m, 3H), 5.96 (d, $J = 8.4$ Hz, 1H), 3.10 (s, 3H), 2.48 (s, 3H), 2.15 (s, 3H).


$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.6, 152.6, 147.4, 140.2, 139.7, 137.7, 136.0, 130.0, 129.4, 126.4, 125.8, 124.2, 122.6, 121.6, 120.7, 118.1, 112.6, 92.5, 45.6, 43.1, 12.6, 12.3, 7.6.

ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3\text{IS}^+ ([\text{M} + \text{H}]^+) = 574.0656$, found 574.0672.

IR (neat): 2361, 2355, 1696, 1353, 1308, 1143, 750, 521 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 25.417 | 4068326 | 50.36 |
| 2 | 32.667 | 4010647 | 49.64 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 25.110 | 11551346 | 97.50 |
| 2 | 32.542 | 296345 | 2.50 |

(*R,E*)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-4-(4-(trifluoromethyl)phenyl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4la)



Following the typical procedure B.

36.6 mg, 71% yield; white solid; M.p. 103–108 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1).

Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 16.381 min, t (minor) = 20.901 min. ee = 89%. $[\alpha]^{24}_D = +56.9$ ($c = 0.58$, in CH_2Cl_2).


¹H NMR (400 MHz, Chloroform-*d*) δ 9.33 (s, 1H), 7.74 (dd, *J* = 15.6, 8.4 Hz, 1H), 7.55 – 7.43 (m, 6H), 7.40 – 7.32 (m, 2H), 7.10 – 7.06 (m, 1H), 6.07 (d, *J* = 8.4 Hz, 1H), 3.13 (s, 3H), 2.48 (s, 3H), 2.15 (s, 3H), 1.90 (s, 3H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.6, 152.7, 146.9, 144.5, 139.8, 136.1, 129.5, 129.3 (d, *J* = 32.0 Hz), 128.3, 126.8 (q, *J* = 275.7 Hz), 126.5, 125.7, 125.6 (q, *J* = 3.6 Hz), 124.5, 122.5, 121.7, 120.4, 118.1, 112.7, 45.7, 43.4, 12.6, 12.3, 7.6.


¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ -62.46.

ESI-HRMS: calcd for C₂₆H₂₅N₃O₃F₃S⁺ ([M + H]⁺) = 516.1563, found 516.1562.

IR (neat): 2360, 2351, 1697, 1354, 1320, 1121, 1067, 10111, 958, 824, 750, 522 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 16.256 | 3286912 | 49.92 |
| 2 | 20.597 | 3297135 | 50.08 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 16.381 | 14627255 | 94.25 |
| 2 | 20.901 | 892518 | 5.75 |

(*R,E*)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-4-(p-tolyl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ma)



Following the typical procedure C.

38.7 mg, 84% yield; white solid; M.p. 100–106 °C. R_f = 0.2 (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 24.881 min, t (minor) = 32.764 min. ee = 94%. [α]¹⁸_D = +65.3 (*c* = 0.53, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.19 (s, 1H), 7.78 (dd, *J* = 15.6, 8.4 Hz, 1H), 7.51 – 7.42 (m, 3H), 7.35 – 7.29 (m, 1H), 7.21 – 7.19 (m, 2H), 7.11 – 7.02 (m, 3H), 5.98 (d, *J* = 8.4 Hz, 1H), 3.06 (s, 3H), 2.48 (s, 3H), 2.30 (s, 3H), 2.15 (s, 3H), 1.89 (s, 3H).


$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.4, 148.6, 139.7, 137.3, 136.5, 136.0, 129.3, 129.2, 127.9, 126.2, 126.1, 123.6, 122.9, 121.6, 121.4, 117.9, 112.5, 45.6, 43.3, 21.0, 12.7, 12.3, 7.6.

ESI-HRMS: calcd for $\text{C}_{26}\text{H}_{28}\text{N}_3\text{O}_3\text{S}^+$ ($[\text{M} + \text{H}]^+$) = 462.1846, found 462.1850.

IR (neat): 1696, 1635, 1380, 1352, 1311, 1187, 1143, 1007, 958, 939, 811, 749, 522 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 24.959 | 6199263 | 49.87 |
| 2 | 32.535 | 6230813 | 50.13 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 24.881 | 19135177 | 97.05 |
| 2 | 32.764 | 582078 | 2.95 |

(*R,E*)-4-(4-methoxyphenyl)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4na)

Following the typical procedure B.



41.1 mg, 86% yield; white solid; M.p. 100–104 °C. $R_f = 0.1$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiracel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 34.050 min, t (minor) = 42.393 min. ee = 91%. $[\alpha]^{23}\text{D} = +47.2$ ($c = 0.69$, in CH_2Cl_2).

^1H NMR (400 MHz, Chloroform-*d*) δ 9.33 (s, 1H), 7.76 (dd, $J = 15.6, 8.0$ Hz, 1H), 7.49 – 7.41 (m, 3H), 7.33 – 7.29 (m, 1H), 7.23 – 7.19 (m, 2H), 7.08 – 7.04 (m, 1H), 6.83 – 6.77 (m, 2H), 5.96 (d, $J = 8.4$ Hz, 1H), 3.76 (s, 3H), 3.05 (s, 3H), 2.48 (s, 3H), 2.14 (s, 3H), 1.89 (s, 3H).


$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 164.9, 158.4, 152.4, 148.8, 139.7, 136.0, 132.5, 129.1, 129.2, 127.9, 126.2, 126.1, 123.5, 122.9, 121.7, 121.4, 117.9, 114.0, 112.5, 77.2, 55.2, 45.4, 42.9, 12.7, 12.3, 7.6.

ESI-HRMS: calcd for $\text{C}_{26}\text{H}_{28}\text{N}_3\text{O}_4\text{S}^+$ ($[\text{M} + \text{H}]^+$) = 478.1795, found 478.1801.

IR (neat): 2362, 2250, 1696, 1634, 1509, 1353, 1303, 1247, 1180, 1143, 1007, 959, 823 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 34.784 | 16722550 | 49.54 |
| 2 | 42.027 | 17034081 | 50.46 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 34.050 | 54177694 | 95.61 |
| 2 | 42.393 | 2487693 | 4.39 |

(S,E)-4-(furan-2-yl)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4oa)



Following the typical procedure B.

29.7 mg, 68% yield; pale yellow solid; M.p. 103–109 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 23.315 min, t (minor) = 26.133 min. ee = 92%. $[\alpha]^{25}_D = +36.7$ ($c = 0.48$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.22 (s, 1H), 7.66 (dd, $J = 15.6, 7.2$ Hz, 1H), 7.59 – 7.57 (m, 1H), 7.50 – 7.42 (m, 2H), 7.37 – 7.28 (m, 2H), 7.13 – 7.09 (m, 1H), 6.33 – 6.25 (m, 2H), 6.03 (d, $J = 7.2$ Hz, 1H), 3.20 (s, 3H), 2.47 (s, 3H), 2.13 (s, 3H), 1.88 (s, 3H).

$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.7, 152.9, 152.4, 145.3, 142.1, 139.6, 135.9, 129.1, 126.3, 125.9, 124.1, 122.6, 121.5, 119.1, 118.0, 112.4, 110.4, 107.1, 45.8, 38.2, 12.7, 12.3, 7.6.


ESI-HRMS: calcd for $\text{C}_{23}\text{H}_{24}\text{N}_3\text{O}_4\text{S}^+$ ($[\text{M} + \text{H}]^+$) = 438.1482, found 438.1484.

IR (neat): 2361, 2356, 1697, 1639, 1353, 1313, 1142, 1009, 959, 747, 522, 433 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|------|--------|
| 1 | 22.342 | 100 | 100 |
| 2 | 26.019 | 100 | 100 |

| | | | |
|---|--------|---------|-------|
| 1 | 22.874 | 4402311 | 50.88 |
| 2 | 26.093 | 4250383 | 49.12 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 23.315 | 14417834 | 95.81 |
| 2 | 26.133 | 630185 | 4.19 |

(R,E)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-4-(thiophen-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4pa)



Following the typical procedure B.

32.1 mg, 70% yield; pale yellow solid; M.p. 90–94 °C. R_f = 0.2 (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IA** column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (minor) = 11.522 min, t (major) = 13.465 min. ee = 94%. [α]²⁴_D = +50.0 (c = 0.49, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.23 (s, 1H), 7.73 (dd, *J* = 15.6, 8.4 Hz, 1H), 7.52 – 7.43 (m, 3H), 7.35 – 7.31 (m, 1H), 7.26 – 7.23 (m, 1H), 7.13 – 7.02 (m, 2H), 6.94 – 6.92 (m, 1H), 5.98 (d, *J* = 8.0, Hz, 1H), 3.10 (s, 3H), 2.48 (s, 3H), 2.15 (s, 3H), 1.89 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.5, 147.9, 140.9, 139.7, 136.0, 128.9, 127.8, 126.3, 126.1, 125.9, 123.3, 122.7, 121.8, 121.4, 121.0, 118.0, 112.5, 45.6, 39.9, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₂₃H₂₄N₃O₃S₂⁺ ([M + H]⁺) = 454.1254, found 454.1262.

IR (neat): 1696, 1636, 1381, 1352, 1311, 1141, 1008, 959, 832, 747, 523, 433 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 11.524 | 44209759 | 49.86 |
| 2 | 13.495 | 44452280 | 50.14 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 11.552 | 1402786 | 3.09 |
| 2 | 13.465 | 44036773 | 96.91 |

(R,E)-4-(2-(methylsulfonyl)-1H-indol-3-yl)-4-(naphthalen-2-yl)-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-2-en-1-one (4qa)



Following the typical procedure B.

43.9 mg, 88% yield; pale yellow solid; M.p. 132–136 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 27.178 min, t (minor) = 36.345 min. ee = 94%. $[\alpha]^{23}_D = +104.1$ ($c = 0.59$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.37 (s, 1H), 7.90 (dd, $J = 15.6, 8.4$ Hz, 1H), 7.83 – 7.76 (m, 3H), 7.74 – 7.72 (m, 1H), 7.57 – 7.53 (m, 1H), 7.47 – 7.44 (m, 4H), 7.41 – 7.39 (m, 1H), 7.33 – 7.28 (m, 1H), 7.04 – 6.98 (m, 1H), 6.20 (d, $J = 8.4$ Hz, 1H), 3.10 (s, 3H), 2.51 (s, 3H), 2.15 (s, 3H).


$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.8, 152.5, 148.2, 139.7, 138.0, 136.1, 133.3, 132.3, 129.4, 128.4, 127.9, 127.6, 126.5, 126.2, 126.2, 126.1, 125.9, 124.0, 122.8, 121.5, 121.2, 118.0, 112.5, 77.2, 45.5, 43.7, 12.7, 12.3, 7.6.

ESI-HRMS: calcd for $\text{C}_{29}\text{H}_{28}\text{N}_3\text{O}_3\text{S}^+ ([\text{M} + \text{H}]^+) = 498.1846$, found 498.1852.

IR (neat): 1696, 1634, 1381, 1352, 1312, 1142, 958, 820, 747, 523, 477, 432 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 27.278 | 25985452 | 50.04 |
| 2 | 35.598 | 25941592 | 49.96 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 27.178 | 84552113 | 97.01 |
| 2 | 36.345 | 2604004 | 2.99 |

(E)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-5-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)pent-2-en-1-one (4ra)



Following the typical procedure B.

2.5 mg, 5% yield; white solid; M.p. 72–78 °C. R_f = 0.3 (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; HPLC (Chiralcel IA column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (minor) = 8.594 min, t (major) = 12.229 min. ee = 78%. [α]²¹_D = -50.0 (c = 0.08, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.82 (s, 1H), 7.60 – 7.58 (m, 1H), 7.46 – 7.38 (m, 3H), 7.26 – 7.22 (m, 2H), 7.15 – 7.08 (m, 3H), 6.94 – 6.92 (m, 2H), 4.82 – 4.76 (m, 1H), 3.51 – 3.45 (m, 1H), 3.39 – 3.35 (m, 1H), 2.46 (s, 3H), 2.37 (s, 3H), 2.17 (s, 3H), 1.89 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 165.3, 155.8, 152.3, 145.5, 139.8, 134.9, 130.2, 128.6, 127.7, 126.9, 126.8, 126.5, 125.6, 123.8, 121.0, 118.5, 117.8, 112.2, 47.3, 44.9, 25.8, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₂₆H₂₈N₃O₃S⁺ ([M + H]⁺) = 462.1846, found 462.1848.

IR (neat): 1696, 1634, 1380, 1352, 1300, 1142, 1089, 1013, 962, 937, 821, 751, 700, 521 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 8.492 | 4789849 | 50.04 |
| 2 | 12.128 | 4781959 | 49.96 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 8.594 | 2016843 | 11.05 |
| 2 | 12.229 | 16239190 | 88.95 |

(E)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)pent-2-en-1-one (4sa)



Following the typical procedure B.


18.0 mg, 39% yield; white solid; M.p. 85-90 °C. $R_f = 0.4$ (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IA** column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (minor) = 15.541 min, t (major) = 18.840 min. ee = 82%. $[\alpha]^{28}_D = -191.5$ ($c = 0.26$, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.25 (s, 1H), 8.04 (d, $J = 16.0$ Hz, 1H), 7.42 – 7.37 (m, 4H), 7.32 – 7.17 (m, 4H), 7.19 – 7.17 (m, 1H), 6.96 (t, $J = 8.0$ Hz, 1H), 2.84 (s, 3H), 2.50 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 1.90 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.9, 152.3, 150.0, 139.5, 135.9, 133.7, 130.2, 129.8, 129.3, 128.4, 126.5, 126.2, 122.7, 121.9, 121.4, 121.0, 117.8, 112.7, 44.8, 42.0, 40.1, 12.8, 12.3, 7.7.

ESI-HRMS: calcd for C₂₆H₂₈N₃O₃S⁺ ([M + H]⁺) = 462.1846, found 462.1848.

IR (neat): 1695, 1630, 1378, 1351, 1321, 1264, 1146, 1027, 735, 702, 529, 434 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 15.496 | 3436950 | 50.62 |
| 2 | 18.799 | 3353364 | 49.38 |



| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 15.541 | 425156 | 8.96 |
| 2 | 18.840 | 4321626 | 91.04 |

(*R,E*)-4-(2-(ethylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ab)



Following the typical procedure B.

35.0 mg, 76% yield; white solid; M.p. 100-104 °C. $R_f = 0.3$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IF** column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 24.761 min, t (minor) = 28.750 min. ee = 92%. $[\alpha]^{18}_D = +83.4$ ($c = 0.70$, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.19 (s, 1H), 7.71 (dd, *J* = 15.6, 8.0 Hz, 1H), 7.42 – 7.35 (m, 3H), 7.26 – 7.13 (m, 6H), 7.00 – 6.96 (m, 1H), 5.91 (d, *J* = 8.0 Hz, 1H), 3.14 – 3.01 (m, 2H), 2.40 (s, 3H), 2.06 (s, 3H), 1.81 (s, 3H), 1.16 (t, *J* = 7.4 Hz, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.3, 148.4, 140.5, 139.7, 136.2, 128.6, 128.0, 127.7, 126.9, 126.1, 126.1, 123.8, 122.9, 121.8, 121.3, 117.9, 112.5, 51.7, 43.6, 12.7, 12.3, 7.6, 7.3.

ESI-HRMS: calcd for C₂₆H₂₈N₃O₃S⁺ ([M + H]⁺) = 462.1846, found 462.1850.

IR (neat): 1696, 1635, 1380, 1352, 1311, 1276, 1185, 1129, 1090, 987, 938, 831, 754, 727, 701, 622, 526, 506 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 24.724 | 2170506 | 50.09 |
| 2 | 28.364 | 2162682 | 49.91 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 24.761 | 23646608 | 96.00 |
| 2 | 28.750 | 984210 | 4.00 |

(*R,E*)-4-phenyl-4-(2-(propylsulfonyl)-1*H*-indol-3-yl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ac)

Following the typical procedure B.




40.5 mg, 84% yield; white solid; M.p. 111–115 °C. R_f = 0.4 (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 27.137 min, t (minor) = 34.282 min. ee = 89%. [α]²⁴_D = +56.5 (*c* = 0.20, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.24 (s, 1H), 7.80 (dd, *J* = 15.6, 8.0 Hz, 1H), 7.51 – 7.43 (m, 3H), 7.36 – 7.26 (m, 5H), 7.24 – 7.19 (m, 1H), 7.08 – 7.04 (m, 1H), 5.98 (d, *J* = 8.0 Hz, 1H), 3.13 – 3.00 (m, 2H), 2.48 (s, 3H), 2.14 (s, 3H), 1.89 (s, 3H), 1.73 – 1.64 (m, 2H), 0.83 (t, *J* = 7.2 Hz, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.3, 148.6, 140.5, 139.6, 136.0, 128.6, 128.2, 128.0, 126.9, 126.2, 126.0, 123.7, 122.9, 121.6, 121.4, 117.9, 112.5, 59.0, 43.7, 16.4, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₂₇H₃₀N₃O₃S⁺ ([M + H]⁺) = 476.2002, found 476.2008.

IR (neat): 1697, 1637, 1381, 1354, 1315, 1181, 1132, 1088, 1011, 959, 846, 803, 760, 728, 701, 531, 430 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 27.391 | 10422587 | 49.35 |
| 2 | 33.940 | 10698578 | 50.65 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 27.137 | 52712748 | 94.60 |
| 2 | 34.282 | 3010237 | 5.40 |

(R,E)-4-(2-(butylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ad)



Following the typical procedure C.

46.4 mg, 95% yield; white solid; M.p. 90–92 °C. $R_f = 0.5$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 23.254 min, t (minor) = 31.040 min. ee = 85%. $[\alpha]^{23}_D = +48.7$ ($c = 0.45$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.21 (s, 1H), 7.80 (dd, $J = 15.6, 8.0$ Hz, 1H), 7.52 – 7.44 (m, 3H), 7.35 – 7.26 (m, 5H), 7.24 – 7.19 (m, 1H), 7.10 – 7.05 (m, 1H), 5.98 (d, $J = 8.4$ Hz, 1H), 3.14 – 3.03 (m, 2H), 2.48 (s, 3H), 2.14 (s, 3H), 1.67 – 1.58 (m, 2H), 1.27 – 1.18 (m, 2H), 0.74 (t, $J = 7.2$ Hz, 3H).

$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.7, 152.3, 148.7, 140.5, 139.6, 136.1, 128.6, 128.3, 128.0, 126.9, 126.2, 126.0, 123.6, 122.9, 121.6, 121.4, 117.9, 112.5, 57.2, 43.7, 24.4, 21.3, 13.3, 12.7, 12.3, 7.7.


ESI-HRMS: calcd for $\text{C}_{28}\text{H}_{32}\text{N}_3\text{O}_3\text{S}^+ ([\text{M} + \text{H}]^+) = 490.2159$, found 490.2162.

IR (neat): 1696, 1635, 1380, 1352, 1294, 1127, 1089, 1005, 936, 745, 701, 625, 522 cm^{-1} .




| | Retention Time | Area | % Area |
|--|----------------|------|--------|
| | | | |

| | | | |
|---|--------|----------|-------|
| 1 | 23.727 | 15389195 | 49.54 |
| 2 | 31.461 | 15673136 | 50.46 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 23.254 | 21171881 | 92.52 |
| 2 | 31.040 | 1711200 | 7.48 |

(R,E)-4-(2-(isobutylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ae)



Following the typical procedure C.

34.2 mg, 70% yield; white solid; M.p. 91–96 °C. $R_f = 0.4$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IA** column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (minor) = 19.974 min, t (major) = 21.6417777 min. ee = 81%. $[\alpha]^{22}_D = +45.6$ ($c = 0.50$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.20 (s, 1H), 7.80 (dd, $J = 15.6, 8.0$ Hz, 1H), 7.53 – 7.44 (m, 3H), 7.37 – 7.26 (m, 5H), 7.24 – 7.20 (m, 1H), 7.10 – 7.05 (m, 1H), 5.98 (d, $J = 8.0$ Hz, 1H), 3.04 – 2.95 (m, 2H), 2.49 (s, 3H), 2.22 – 2.17 (m, 1H), 2.15 (s, 3H), 1.90 (s, 3H), 0.96 – 0.92 (m, 6H).


$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.7, 152.3, 148.6, 140.5, 139.6, 136.0, 129.1, 128.6, 128.1, 126.9, 126.2, 126.0, 123.6, 122.9, 121.4, 121.3, 117.9, 112.5, 65.0, 43.8, 24.0, 22.5, 22.5, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for $\text{C}_{28}\text{H}_{32}\text{N}_3\text{O}_3\text{S}^+ ([\text{M} + \text{H}]^+) = 490.2159$, found 490.2153.

IR (neat): 1696, 1635, 1380, 1352, 1230, 1130, 1086, 1006, 938, 832, 746, 700, 627, 518 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 19.693 | 5631621 | 49.79 |
| 2 | 21.513 | 5679543 | 50.21 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 19.974 | 4731951 | 9.65 |
| 2 | 21.641 | 44278422 | 90.35 |

(R,E)-4-(2-(dodecylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4af)



Following the typical procedure B.

41.8 mg, 70% yield; colorless oil; $R_f = 0.5$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 16.883 min, t (minor) = 22.012 min. ee = 85%. $[\alpha]^{23}_D = +53.8$ ($c = 0.71$, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.29 (s, 1H), 7.80 (dd, $J = 15.6, 8.4$ Hz, 1H), 7.55 – 7.42 (m, 3H), 7.34 – 7.19 (m, 6H), 7.08 – 7.04 (m, 1H), 5.99 (d, $J = 8.4$ Hz, 1H), 3.10 – 3.06 (m, 2H), 2.48 (s, 3H), 2.14 (s, 3H), 1.89 (s, 3H), 1.69 – 1.55 (m, 2H), 1.29 – 1.03 (m, 18H), 0.87 (t, $J = 6.8$ Hz, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.7, 152.3, 148.7, 140.6, 139.6, 136.1, 128.6, 128.2, 128.0, 126.9, 126.2, 126.0, 123.6, 122.9, 121.6, 121.3, 117.9, 112.5, 57.4, 43.7, 31.9, 29.5, 29.3, 29.2, 28.8, 28.0, 22.6, 22.6, 14.1, 12.7, 12.3, 7.6.

ESI-HRMS: calcd for C₃₆H₄₈N₃O₃S⁺ ([M + H]⁺) = 602.3411, found 602.3421.

IR (neat): 2852, 1699, 1635, 1380, 1352, 1296, 1129, 1006, 745, 523 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 17.066 | 6138805 | 50.56 |
| 2 | 21.958 | 6002792 | 49.44 |



| | Retention Time | Area | % Area |
|--|----------------|------|--------|
| | | | |

| | | | |
|---|--------|----------|-------|
| 1 | 16.883 | 44878308 | 92.68 |
| 2 | 22.012 | 3545345 | 7.32 |

(R,E)-4-(2-(benzylsulfonyl)-1H-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-2-en-1-one (4ag)



Following the typical procedure D.

39.1 mg, 75% yield; pale yellow solid; M.p. 96-100 °C. $R_f = 0.3$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 30.322 min, t (minor) = 36.249 min. ee = 87%. $[\alpha]^{20}_D = +50.2$ ($c = 0.76$, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.82 (s, 1H), 7.78 (dd, *J* = 15.6, 8.0 Hz, 1H), 7.52 – 7.45 (m, 2H), 7.36 – 7.25 (m, 6H), 7.24 – 7.19 (m, 2H), 7.17 – 7.12 (m, 2H), 7.07 – 6.99 (m, 3H), 6.02 (d, *J* = 8.0, 1H), 4.35 – 4.25 (m, 2H), 2.48 (s, 3H), 2.10 (s, 3H), 1.87 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.4, 148.8, 140.6, 139.6, 136.0, 130.7, 129.0, 128.6, 128.6, 128.2, 127.3, 127.2, 126.9, 126.1, 125.8, 123.6, 122.8, 122.5, 121.3, 117.9, 112.4, 63.4, 43.6, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₃₁H₃₀N₃O₃S⁺ ([M + H]⁺) = 524.2002, found 524.2008.

IR (neat): 1693, 1634, 1380, 1351, 1312, 1190, 1147, 1117, 1089, 1005, 936, 914, 871, 830, 726, 696, 640, 601, 516, 430 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 30.638 | 3300653 | 49.74 |
| 2 | 36.154 | 3335086 | 50.26 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 30.322 | 15736056 | 93.51 |
| 2 | 36.249 | 1092402 | 6.49 |

(R,E)-4-phenyl-4-(2-(phenylsulfonyl)-1H-indol-3-yl)-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-2-en-1-one (4ah)



Following the typical procedure B.

31.6 mg, 62% yield; white solid; M.p. 87-91 °C. $R_f = 0.3$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IF** column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 28.159 min, t (minor) = 35.053 min. ee = 20%. $[\alpha]^{22}_D = +17.2$ ($c = 0.60$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.18 (s, 1H), 7.93 – 7.91 (m, 2H), 7.65 (dd, $J = 15.6, 8.4$ Hz, 1H), 7.43 – 7.32 (m, 6H), 7.31 – 7.28 (m, 1H), 7.20 – 7.12 (m, 5H), 7.02 – 6.98 (m, 1H), 6.00 (d, $J = 8.4$ Hz, 1H), 2.46 (s, 3H), 2.19 (s, 3H), 1.91 (s, 3H).


$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.7, 152.1, 147.8, 141.4, 140.3, 139.6, 136.2, 133.3, 130.2, 129.3, 128.4, 127.9, 127.1, 126.7, 126.2, 126.1, 123.7, 122.9, 121.4, 121.3, 117.8, 112.4, 43.5, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for $\text{C}_{30}\text{H}_{28}\text{N}_3\text{O}_3\text{S}^+ ([\text{M} + \text{H}]^+) = 510.1846$, found 510.1848.

IR (neat): 1694, 1634, 1353, 1304, 1184, 1147, 1086, 1005, 936, 831, 749, 723, 618, 549, 431 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 28.228 | 2903889 | 50.06 |
| 2 | 35.120 | 2897487 | 49.94 |



| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 28.159 | 1859627 | 60.21 |
| 2 | 35.053 | 1228756 | 39.79 |

(*R,E*)-4-(5-chloro-2-(methylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ai)



Following the typical procedure B.

36.4 mg, 76% yield; white solid; M.p. 110-114 °C. $R_f = 0.2$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IE** column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 14.679 min, t (minor) = 18.418 min. ee = 94%. $[\alpha]^{22}_D = +103.2$ ($c = 0.72$, in CH_2Cl_2).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.57 (s, 1H), 7.71 (dd, *J* = 15.6, 8.4, 1.2 Hz, 1H), 7.48 – 7.44 (m, 1H), 7.38 – 7.34 (m, 2H), 7.29 – 7.23 (m, 6H), 5.97 (d, *J* = 8.4 Hz, 1H), 3.07 (s, 3H), 2.49 (s, 3H), 2.14 (s, 3H), 1.90 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.6, 147.7, 139.9, 139.8, 134.3, 130.6, 128.7, 127.9, 127.2, 127.1, 126.9, 126.8, 124.2, 121.8, 120.7, 118.0, 113.8, 45.4, 43.4, 12.7, 12.3, 7.6.

ESI-HRMS: calcd for C₂₅H₂₅N₃O₃³⁵ClS⁺ ([M + H]⁺) = 482.1300, found 482.1299. C₂₅H₂₅N₃O₃³⁷ClS⁺ ([M + H]⁺) = 484.1270, found 484.1271.

IR (neat): 1696, 1635, 1354, 1307, 1137, 960, 758, 701, 535, 431 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 14.738 | 4244328 | 49.42 |
| 2 | 18.230 | 4344377 | 50.58 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 14.679 | 15454206 | 97.13 |
| 2 | 18.418 | 456355 | 2.87 |

(*R,E*)-4-(5-bromo-2-(methylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4aj)

Following the typical procedure C.



45.5 mg, 87% yield; white solid; M.p. 107–111 °C. R_f = 0.2 (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 18.909 min, t (minor) = 23.142 min. ee = 95%. [α]¹⁷_D = +126.5 (*c* = 0.43, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.27 (s, 1H), 7.69 (dd, *J* = 15.4, 8.4, 1H), 7.52 – 7.41 (m, 2H), 7.38 – 7.35 (m, 1H), 7.31 – 7.22 (m, 6H), 5.94 (d, *J* = 8.4 Hz, 1H), 3.05 (s, 3H), 2.47 (s, 3H), 2.13 (s, 3H), 1.88 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.7, 152.6, 147.6, 139.8, 139.8, 134.4, 130.4, 129.4, 128.7, 127.9, 127.4, 127.2, 124.9, 124.1, 120.6, 118.1, 114.6, 114.1, 45.4, 43.3, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₂₅H₂₅N₃O₃⁷⁹BrS⁺ ([M + H]⁺) = 526.0795, found 526.0798. C₂₅H₂₅N₃O₃⁸¹BrS⁺ ([M + H]⁺) = 528.0774, found 528.0779.

IR (neat): 1697, 1636, 1381, 1354, 1308, 1137, 1005, 959, 937, 802, 759, 700, 533, 429 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 19.049 | 5699916 | 50.00 |
| 2 | 22.973 | 5699393 | 50.00 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 18.909 | 34632145 | 97.51 |
| 2 | 23.142 | 884361 | 2.49 |

(R,E)-4-(5-methoxy-2-(methylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ak)

Following the typical procedure C.



38.0 mg, 80% yield; white solid; M.p. 111–116 °C. R_f = 0.2 (Pet/EtOAc = 3/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IF column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 30.334 min, t (minor) = 34.237 min. ee = 95%. [α]¹⁸_D = +123.0 (c = 0.30, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.05 (s, 1H), 7.73 (dd, *J* = 15.6, 8.0 Hz, 1H), 7.47 – 7.42 (m, 1H), 7.34 – 7.27 (m, 5H), 7.25 – 7.21 (m, 1H), 7.00 – 6.97 (m, 1H), 6.73 – 6.72 (m, 1H), 6.00 (d, *J* = 8.0 Hz, 1H), 3.60 (s, 3H), 3.04 (s, 3H), 2.46 (s, 3H), 2.12 (s, 3H), 1.88 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.9, 154.6, 152.4, 148.1, 140.3, 139.6, 131.2, 129.5, 128.6, 128.1, 126.9, 126.5, 123.8, 120.6, 118.0, 117.9, 113.4, 102.6, 55.4, 45.4, 43.5, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₂₆H₂₈N₃O₄S⁺ ([M + H]⁺) = 478.1795, found 478.1800.


IR (neat): 1696, 1634, 1456, 1380, 1354, 1308, 1218, 1178, 1133, 1081, 1024, 1005, 968, 941, 836, 807, 759, 703, 622, 517, 434 cm⁻¹.



| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 30.241 | 5902159 | 50.86 |
| 2 | 33.739 | 5703648 | 49.14 |



(R,E)-4-(6-fluoro-2-(methylsulfonyl)-1H-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-2-en-1-one (4al)



Following the typical procedure B.

35.2 mg, 76% yield; pale yellow solid; M.p. 91–96 °C. $R_f = 0.3$ (Pet/EtOAc = 4/1).

Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 15.172 min, t (minor) = 19.361 min. ee = 96%. $[\alpha]^{21}_D = +76.4$ ($c = 0.42$, in CH_2Cl_2).


$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.35 (s, 1H), 7.73 (dd, $J = 15.6, 8.0$ Hz, 1H), 7.48 – 7.44 (m, 1H), 7.39 – 7.35 (m, 1H), 7.30 – 7.26 (m, 4H), 7.26 – 7.22 (m, 1H), 7.12 – 7.09 (m, 1H), 6.85 – 6.80 (m, 1H), 6.00 (d, $J = 8.0$, 1H), 3.06 (s, 3H), 2.49 (s, 3H), 2.15 (s, 3H), 1.90 (s, 3H).

$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.8, 161.9 (d, $J = 243.3$ Hz), 152.6, 148.0, 140.2, 139.8, 136.2 (d, $J = 12.6$ Hz), 130.0 (d, $J = 38.6$ Hz), 129.7 (d, $J = 3.8$ Hz), 128.7, 128.0, 127.1, 124.3 (d, $J = 10.2$ Hz), 124.0, 122.2 (d, $J = 87.4$ Hz), 118.05, 111.3 (d, $J = 25.0$ Hz), 98.4 (d, $J = 25.9$ Hz), 45.5, 43.5, 12.7, 12.3, 7.7.


$^{19}\text{F}\{^1\text{H}\} \text{NMR}$ (376 MHz, CDCl_3) δ -113.86.

ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3\text{FS}^+ ([\text{M} + \text{H}]^+) = 466.1595$, found 466.1599.

IR (neat): 1696, 1629, 1354, 1303, 1191, 1133, 957, 756, 702, 557, 488 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 15.200 | 10477926 | 49.89 |
| 2 | 19.234 | 10525882 | 50.11 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 15.172 | 19182322 | 98.02 |
| 2 | 19.361 | 388009 | 1.98 |

(R,E)-4-(6-chloro-2-(methylsulfonyl)-1H-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-2-en-1-one (4am)



Following the typical procedure C.

44.9 mg, 93% yield; white solid; M.p. 120–125 °C. $R_f = 0.3$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 14.252 min, t (minor) = 17.824 min. ee = 96%. $[\alpha]^{21}_D = +84.9$ ($c = 0.59$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.37 (s, 1H), 7.70 (dd, $J = 15.6, 8.4$ Hz, 1H), 7.47 – 7.40 (m, 2H), 7.32 – 7.21 (m, 6H), 7.00 – 6.98 (m, 1H), 5.98 (d, $J = 8.4$, 1H), 3.05 (s, 3H), 2.47 (s, 3H), 2.13 (s, 3H), 1.88 (s, 3H).


$^{13}\text{C}\{\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.8, 152.6, 147.9, 140.1, 139.7, 136.2, 132.3, 129.9, 128.7, 127.9, 127.1, 124.5, 124.1, 123.8, 122.5, 121.6, 118.1, 112.3, 45.4, 43.4, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3^{35}\text{ClS}^+ ([\text{M} + \text{H}]^+) = 482.1300$, found 482.1299. $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3^{37}\text{ClS}^+ ([\text{M} + \text{H}]^+) = 484.1270$, found 484.1271.

IR (neat): 1696, 1354, 1314, 1274, 1132, 959, 847, 757, 701, 534 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 14.277 | 10644440 | 50.07 |
| 2 | 17.645 | 10615350 | 49.93 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 14.252 | 12964558 | 97.96 |
| 2 | 17.824 | 269612 | 2.04 |

(R,E)-4-(6-bromo-2-(methylsulfonyl)-1H-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-2-en-1-one (4an)



Following the typical procedure C.

45.6 mg, 87% yield; white solid; M.p. 105–109 °C. R_f = 0.3 (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 14.776 min, t (minor) = 18.503 min. ee = 95%. [α]²²_D = +74.1 (c = 0.46, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.40 (s, 1H), 7.69 (dd, *J* = 15.6, 8.0, 1H), 7.59 – 7.57 (m, 1H), 7.45 – 7.40 (m, 1H), 7.28 – 7.26 (m, 4H), 7.25 – 7.21 (m, 2H), 7.14 – 7.11 (m, 1H), 5.97 (d, *J* = 8.0, 1H), 3.04 (s, 3H), 2.47 (s, 3H), 2.13 (s, 3H), 1.88 (s, 3H).


¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.6, 147.9, 140.1, 139.8, 136.6, 130.2, 129.8, 128.7, 127.9, 127.1, 125.1, 124.8, 124.0, 121.6, 120.1, 118.1, 115.4, 45.4, 43.4, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for C₂₅H₂₅N₃O₃⁷⁹BrS⁺ ([M + H]⁺) = 526.0795, found 526.0796. C₂₅H₂₅N₃O₃⁸¹BrS⁺ ([M + H]⁺) = 528.0774, found 528.0779.

IR (neat): 1696, 1637, 1381, 1354, 1314, 1276, 1182, 1132, 1088, 1007, 959, 845, 803, 757, 701, 530 cm⁻¹.




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 14.842 | 5636851 | 50.13 |
| 2 | 18.342 | 5607945 | 49.87 |



| | Retention Time | Area | % Area |
|--|----------------|------|--------|
| | | | |

| | | | |
|---|--------|----------|-------|
| 1 | 14.776 | 15892912 | 97.51 |
| 2 | 18.503 | 359045 | 2.49 |

(R,E)-4-(7-bromo-2-(methylsulfonyl)-1H-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-2-en-1-one (4ao)



Following the typical procedure B.

30.4 mg, 58% yield; white solid; M.p. 102–105 °C. $R_f = 0.3$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 20.808 min, t (minor) = 24.880 min. ee = 48%. $[\alpha]^{21}_D = +33.3$ ($c = 0.21$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.97 (s, 1H), 7.73 (dd, $J = 15.6, 8.0$ Hz, 1H), 7.51 – 7.40 (m, 3H), 7.31 – 7.28 (m, 4H), 7.26 – 7.22 (m, 1H), 6.98 – 6.94 (m, 1H), 6.01 (d, $J = 8.0$, 1H), 3.09 (s, 3H), 2.48 (s, 3H), 2.15 (s, 3H), 1.90 (s, 3H).


$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.6, 152.5, 147.7, 140.0, 139.7, 134.7, 130.2, 128.7, 128.5, 128.0, 127.1, 127.1, 124.1, 122.6, 122.5, 122.2, 118.0, 105.7, 45.4, 43.6, 26.9, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3^{79}\text{BrS}^+$ ($[\text{M} + \text{H}]^+$) = 526.0795, found 526.0796. $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_3^{81}\text{BrS}^+$ ($[\text{M} + \text{H}]^+$) = 528.0774, found 528.0771.

IR (neat): 2361, 2310, 1695, 1636, 1425, 1381, 1354, 1316, 1187, 1141, 1092, 961 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 20.726 | 11970687 | 49.65 |
| 2 | 24.603 | 12141059 | 50.35 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 20.808 | 20585135 | 73.90 |
| 2 | 24.880 | 7270801 | 26.10 |

(R,E)-4-(6-chloro-5-(2-chloroethyl)-2-(methylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (4ap)



Following the typical procedure C.

51.5 mg, 95% yield; white solid; M.p. 95–101 °C. $R_f = 0.3$ (Pet/EtOAc = 4/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 14.514 min, t (minor) = 23.941 min. ee = 95%. $[\alpha]^{25}_D = +86.8$ ($c = 0.59$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.39 (s, 1H), 7.71 (dd, $J = 15.6, 8.0$ Hz, 1H), 7.48 – 7.43 (m, 2H), 7.47 – 7.42 (m, 1H), 7.31 – 7.28 (m, 5H), 7.25 – 7.21 (m, 1H), 5.99 (d, $J = 8.0$, 1H), 3.65 – 3.56 (m, 2H), 3.18 – 3.08 (m, 2H), 3.07 (s, 3H), 2.49 (s, 3H), 2.14 (s, 3H), 1.90 (s, 3H).


$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 164.8, 152.6, 147.9, 139.9, 139.8, 135.4, 132.5, 130.3, 128.8, 128.7, 128.0, 127.2, 125.0, 124.8, 124.1, 121.3, 118.1, 113.2, 45.4, 43.5, 43.4, 37.0, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for $\text{C}_{27}\text{H}_{28}\text{N}_3\text{O}_3^{35}\text{Cl}_2\text{S}^+$ ($[\text{M} + \text{H}]^+$) = 544.1223, found 544.1226. $\text{C}_{27}\text{H}_{28}\text{N}_3\text{O}_3^{35}\text{Cl}^{37}\text{ClS}^+$ ($[\text{M} + \text{H}]^+$) = 546.1193, found 546.1197. $\text{C}_{27}\text{H}_{28}\text{N}_3\text{O}_3^{37}\text{Cl}_2\text{S}^+$ ($[\text{M} + \text{H}]^+$) = 548.1164, found 548.1168.

IR (neat): 1696, 1633, 1354, 1311, 1175, 1132, 956, 853, 756, 702, 558 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 14.482 | 17417640 | 50.01 |
| 2 | 23.678 | 17410576 | 49.99 |



| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 14.514 | 9597395 | 97.34 |
| 2 | 23.941 | 261762 | 2.66 |

(E)-4-(2-(ethylthio)-3-methyl-3*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (3aq)



Following the typical procedure E.

22.9 mg, 52% yield; pale yellow oil. $R_f = 0.2$ (Pet/EtOAc = 10/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IA** column), n-hexane/i-PrOH = 98/2, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: $t_{\text{minor isomer}} (\text{minor}) = 5.405$ min, $t_{\text{major isomer}} (\text{major}) = 6.609$ min. $t_{\text{major isomer}} (\text{minor}) = 9.698$ min, $t_{\text{minor isomer}} (\text{major}) = 13.217$ min. 80:20 dr (determined by ^1H NMR analysis), 89% ee (major), 77% ee (minor). $[\alpha]^{22}_D = +82.4$ ($c = 0.45$, in CH_2Cl_2).

^1H NMR (400 MHz, Chloroform-*d*) δ 7.54 – 7.28 (m, 3H), 7.26 – 7.18 (m, 3H), 7.15 – 6.94 (m, 4H), 6.91 – 6.89 (m, 0.8H), 6.68 – 6.66 (m, 0.2H), 4.00 (d, $J = 10.0$ Hz, 0.8H), 3.95 (d, $J = 10.0$ Hz, 0.2H), 3.86 – 3.30 (m, 0.8H), 3.25 – 3.19 (m, 0.8H), 3.15 – 3.10 (m, 0.2H), 3.08 – 3.01 (m, 0.2H), 2.52 (s, 0.6 H), 2.44 (s, 2.4 H), 2.22 (s, 0.6 H), 2.17 (s, 2.4 H), 1.92 (s, 0.6 H), 1.88 (s, 2.4 H), 1.48 (s, 0.6 H), 1.41 (t, $J = 7.2$ Hz, 2.4H), 1.33 (s, 0.6 H), 1.26 – 1.23 (m, 0.6H).


$^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 164.3, 155.0, 152.1, 146.8, 140.9, 137.8, 129.6, 128.3, 127.9, 127.3, 123.9, 123.42, 123.40, 118.7, 117.7, 61.9, 55.7, 25.3, 22.9, 14.1, 12.7, 12.3, 7.6.

ESI-HRMS: calcd for $\text{C}_{27}\text{H}_{30}\text{N}_3\text{OS}^+ ([\text{M} + \text{H}]^+) = 444.2104$, found 444.2102.

IR (neat): 2926, 1701, 1638, 1507, 1452, 1353, 1007, 770, 708 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 5.248 | 5525888 | 14.17 |
| 2 | 6.460 | 14038671 | 35.99 |
| 3 | 9.556 | 14034772 | 35.98 |
| 4 | 12.983 | 5408318 | 13.86 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 5.405 | 684669 | 2.14 |
| 2 | 6.609 | 23460238 | 73.49 |
| 3 | 9.698 | 1401843 | 4.39 |
| 4 | 13.217 | 6377267 | 19.98 |

(R)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)butan-1-one (5aa)



78.1 mg, 87% yield; white solid; M.p. 85–88 °C. $R_f = 0.4$ (Pet/EtOAc = 3/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IC** column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (major) = 24.882 min, t (minor) = 31.536 min. ee = 97%. $[\alpha]^{21}_D = +42.3$ ($c = 0.44$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.03 (s, 1H), 7.72 (d, $J = 8.4$ Hz, 1H), 7.39 – 7.33 (m, 3H), 7.26 – 7.16 (m, 3H), 7.10 – 7.03 (m, 2H), 4.99 (d, $J = 8.0$, 1H), 3.18 – 2.95 (m, 2H), 2.95 (s, 3H), 2.81 – 2.63 (m, 2H), 2.33 (s, 3H), 2.01 (s, 3H), 1.77 (s, 3H).


$^{13}\text{C}\{^1\text{H}\} \text{NMR}$ (100 MHz, Chloroform-*d*) δ 173.3, 152.0, 142.7, 139.3, 136.0, 129.3, 128.4, 127.9, 126.4, 126.3, 125.9, 124.0, 123.0, 121.1, 117.1, 112.5, 45.4, 40.3, 34.0, 29.1, 12.6, 12.2, 7.5.

ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{28}\text{N}_3\text{O}_3\text{S}^+ ([\text{M} + \text{H}]^+) = 450.1846$, found 450.1846.

IR (neat): 3316, 1714, 1492, 1303, 1189, 1141, 957, 931, 835, 746, 702, 588, 523, 431 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 24.852 | 18911670 | 50.50 |
| 2 | 31.385 | 18539925 | 49.50 |



| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 24.882 | 5406861 | 98.62 |
| 2 | 31.536 | 75511 | 1.38 |

methyl ((*R*)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-4-phenylbutanoyl)-*L*-leucinate (6aa)



19.4 mg, 80% yield; white solid; M.p. 90–94 °C. $R_f = 0.2$ (Pet/EtOAc = 2/1). >19:1 dr (determined by $^1\text{H NMR}$ analysis). $[\alpha]^{19}_D = +21.8$ ($c = 0.22$, in CH_2Cl_2).

$^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.00 (s, 1H), 7.77 (d, $J = 8.4$ Hz, 1H), 7.46 – 7.44 (m, 1H), 7.39 – 7.34 (m, 3H), 7.28 – 7.24 (m, 2H), 7.19 – 7.13 (m, 2H), 5.91 (d, $J = 8.0$ Hz, 1H), 4.93 – 4.89 (m, 1H), 4.64 – 4.58 (m, 1H),


3.70 (s, 3H), 2.98 (s, 3H), 2.77 – 2.61 (m, 2H), 2.36 – 2.30 (m, 1H), 2.24 – 2.16 (m, 1H), 1.66 (s, 1H), 1.61 – 1.47 (m, 2H), 0.92 (t, J = 6.0 Hz, 6H).

$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 173.6, 172.3, 142.5, 135.8, 129.6, 128.5, 127.9, 126.5, 126.1, 123.4, 123.0, 121.3, 112.6, 52.2, 50.7, 45.3, 41.6, 40.4, 34.7, 30.3, 24.8, 22.8, 22.0.

ESI-HRMS: calcd for $\text{C}_{26}\text{H}_{33}\text{N}_2\text{O}_5\text{S}^+$ ($[\text{M} + \text{H}]^+$) = 485.2105, found 485.2104.

IR (neat): 3353, 2957, 2361, 1740, 1654, 1527, 1445, 1310, 1204, 1144, 959, 751, 701, 525 cm^{-1} .

methy l (*R*)-4-(2-(methylsulfonyl)-1*H*-indol-3-yl)-4-phenylbutanoate (7aa)


 17.6 mg, 95% yield; white solid; M.p. 49–53 °C. R_f = 0.2 (Pet/EtOAc = 4/1). Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel IE column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, λ = 254 nm, retention time: t (major) = 33.061 min, t (minor) = 40.515 min. ee = 97%. $[\alpha]^{19}\text{D}$ = +35.8 (c = 0.26, in CH_2Cl_2).

^1H NMR (400 MHz, Chloroform-*d*) δ 8.98 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.46 – 7.34 (m, 4H), 7.29 – 7.25 (m, 2H), 7.20 – 7.13 (m, 2H), 4.97 – 4.93 (m, 1H), 3.60 (s, 3H), 2.94 (s, 3H), 2.76 – 2.60 (m, 2H), 2.47 – 2.27 (m, 2H).


$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 173.7, 142.5, 135.9, 129.5, 128.5, 127.9, 126.5, 126.4, 126.1, 123.5, 122.8, 121.3, 112.6, 51.5, 45.3, 40.2, 32.5, 29.5.

ESI-HRMS: calcd for $\text{C}_{20}\text{H}_{22}\text{NO}_4\text{S}^+$ ($[\text{M} + \text{H}]^+$) = 372.1264, found 372.1269.

IR (neat): 2361, 1729, 1445, 1307, 1143, 957, 752, 700, 525 cm^{-1} .



| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 33.311 | 2709119 | 50.11 |
| 2 | 40.067 | 2696782 | 49.89 |



| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 33.061 | 5561369 | 98.47 |
| 2 | 40.515 | 86614 | 1.53 |

(R)-4-(2-(methylsulfonyl)-1H-indol-3-yl)-4-phenylbutan-1-ol (8aa)



47.1 mg, 96% yield; white solid; M.p. 58–61 °C. $R_f = 0.2$ (Pet/EtOAc = 2/1).
 Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IC** column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: t (minor) = 21.326 min, t (major) = 28.040 min. ee = 97%. $[\alpha]^{21}_D = +35.4$ ($c = 0.84$, in CH₂Cl₂).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.30 (s, 1H), 7.68 (d, $J = 8.4$ Hz, 1H), 7.36 – 7.29 (m, 3H), 7.25 – 7.21 (m, 1H), 7.18 – 7.14 (m, 2H), 7.10 – 7.01 (m, 2H), 4.87 (t, $J = 8.0$ Hz, 1H), 3.56 (t, $J = 6.4$ Hz, 2H), 2.82 (s, 3H), 2.34 (q, $J = 8.0$ Hz, 2H), 1.83 – 1.80 (m, 1H), 1.62 – 1.53 (m, 1H), 1.46 – 1.37 (m, 1H).

¹³C{¹H} NMR (100 MHz, Chloroform-*d*) δ 143.3, 136.0, 129.1, 128.4, 127.8, 126.4, 126.3, 125.9, 124.3, 122.8, 121.1, 112.6, 62.5, 45.3, 40.7, 31.2, 30.9.

ESI-HRMS: calcd for C₁₉H₂₂NO₃S⁺ ([M + H]⁺) = 344.1315, found 344.1316.

IR (neat): 3316, 1520, 1447, 1299, 1189, 1132, 1053, 957, 744, 700, 578, 522, 431 cm⁻¹.



(1*R*,2*S*,*E*)-4-(2-(methylsulfinyl)-1*H*-indol-3-yl)-4-phenyl-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (9aa)

10.8 mg, 50% yield; white solid; M.p. 113–117 °C. $R_f = 0.2$ (Pet/EtOAc = 1/1).
 Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **ID** column), n-hexane/i-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 220$ nm, retention time: t_{major isomer} (major) = 35.759 min, t_{major isomer} (minor) = 58.670 min. t_{minor isomer} (minor) = 28.885 min, t_{minor isomer} (major) = 49.096 min. 92:8 dr (determined)


by ^1H NMR analysis), 99% ee (major). $[\alpha]^{19}\text{D} = -219.1$ ($c = 0.11$, in CH_2Cl_2).

^1H NMR (400 MHz, Chloroform-*d*) δ 10.22 (s, 1H), 7.67 (dd, $J = 15.6, 8.0$ Hz, 1H), 7.51 (d, $J = 8.4$ Hz, 1H), 7.42 – 7.38 (m, 2H), 7.30 – 7.28 (m, 3H), 7.26 – 7.22 (m, 3H), 7.08 – 7.04 (m, 1H), 5.43 (d, $J = 8.0$ Hz, 1H), 2.84 (s, 3H), 2.49 (s, 3H), 2.16 (s, 3H), 1.90 (s, 3H).


$^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 164.7, 152.4, 149.3, 140.7, 139.7, 137.3, 133.1, 128.8, 128.0, 127.2, 126.6, 124.6, 123.1, 120.8, 120.7, 117.9, 117.9, 112.3, 45.1, 42.3, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for $\text{C}_{25}\text{H}_{26}\text{N}_3\text{O}_2\text{S}^+ ([\text{M} + \text{H}]^+) = 432.1740$, found 432.1745.

IR (neat): 2361, 1699, 1636, 1380, 1353, 1284, 1025, 748, 701 cm^{-1} .




| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 28.970 | 7551734 | 21.93 |
| 2 | 36.239 | 9787482 | 28.42 |
| 3 | 49.212 | 7441539 | 21.61 |
| 4 | 58.942 | 9661530 | 28.05 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 28.885 | 1314145 | 4.07 |
| 2 | 35.759 | 29421903 | 91.18 |
| 3 | 49.096 | 1484824 | 4.60 |
| 4 | 58.670 | 46388 | 0.14 |

(1*R*,2*S*,*E*)-4-(2-(methylsulfinyl)-1*H*-indol-3-yl)-4-(o-tolyl)-1-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)but-2-en-1-one (9da)



33.1 mg, 84% yield; white solid; M.p. 170–175 °C. $R_f = 0.2$ (Pet/EtOAc = 1/1).


Dissolved in isopropanol for HPLC; **HPLC** (Chiralcel **IB** column), n-hexane/i-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 254$ nm, retention time: $t_{\text{minor isomer}} (\text{minor}) = 10.502$ min, $t_{\text{major isomer}} (\text{minor}) = 10.983$ min. $t_{\text{minor isomer}} (\text{major}) = 13.591$ min, $t_{\text{major isomer}} (\text{minor}) = 15.928$ min. > 19:1 dr (determined by ^1H NMR analysis), 97% ee (major). $[\alpha]^{19}_{\text{D}} = -214.0$ ($c = 0.20$, in CH_2Cl_2).

^1H NMR (400 MHz, Chloroform-*d*) δ 10.53 (s, 1H), 7.60 (dd, $J = 15.6, 7.2$ Hz, 1H), 7.53 – 7.51 (m, 1H), 7.35 – 7.33 (m, 1H), 7.24 – 7.10 (m, 6H), 7.08 – 7.04 (m, 1H), 5.53 (d, $J = 7.2$ Hz, 1H), 2.77 (s, 3H), 2.47 (s, 3H), 2.23 (s, 3H), 2.10 (s, 3H), 1.87 (s, 3H).


$^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, Chloroform-*d*) δ 164.8, 152.3, 149.4, 139.7, 138.7, 137.1, 136.5, 133.1, 130.9, 128.2, 127.5, 127.0, 126.3, 124.5, 123.2, 120.6, 120.4, 117.9, 112.3, 110.0, 42.13, 42.06, 19.8, 12.7, 12.3, 7.7.

ESI-HRMS: calcd for $\text{C}_{26}\text{H}_{28}\text{N}_3\text{O}_2\text{S}^+ ([\text{M} + \text{H}]^+) = 446.1897$, found 446.1893.

IR (neat): 2922, 1698, 1634, 1377, 1352, 1089, 1023, 742 cm^{-1} .



| | Retention Time | Area | % Area |
|---|----------------|---------|--------|
| 1 | 10.892 | 1395443 | 35.43 |
| 2 | 11.805 | 575872 | 14.62 |
| 3 | 13.496 | 1410469 | 35.81 |
| 4 | 16.626 | 556962 | 14.14 |



| | Retention Time | Area | % Area |
|---|----------------|----------|--------|
| 1 | 10.502 | 85390 | 0.49 |
| 2 | 10.983 | 257150 | 1.49 |
| 3 | 13.591 | 588102 | 3.40 |
| 4 | 15.928 | 16349968 | 94.61 |



12 References

1. X. B. Lin, Y. Tang, W. Yang, F. Tan, L. L. Lin, X. H. Liu and X. M. Feng, *J. Am. Chem. Soc.*, 2018, **140**, 3299.
2. R. Z. Guo, J. C. Huang and X. D. Zhao, *ACS Catal.*, 2018, **8**, 926.
3. L. K. Ransborg, L. Albrecht, C. F. Weise, J. R. Bak and K. A. Jørgensen, *Org. Lett.*, 2012, **14**, 724.


4. S. P. Zhou, G. H. Xiao and Y. Liang, *Tetrahedron Letters*, 2017, **58**, 338.
5. V. Boyarskikh, A. Nyong and J. D. Rainier, *Angew. Chem., Int. Ed.*, 2008, **47**, 5374.
6. Y. H. Wen, X. Huang, J. L. Huang, Y. Xiong, B. Qin and X. M. Feng, *Synlett.*, 2005, **16**, 2445.
7. W. R. Carroll, C. Zhao, M. D. Smith, P. J. Pellechia and K. D. Shimizu, *Org. Lett.*, 2011, **13**, 4320.
8. E. Schiebel, S. Santacroce, L. Falivene, I. Göttker-Schnetmann, L. Caporaso, and S. Mecking, *ACS Catal.*, 2019, **9**, 3888.
9. D. Uraguchi, K. Yamada and T. Ooi, *Angew. Chem., Int. Ed.*, 2015, **54**, 9954.
10. K. Ishihara and M. Fushimi, *J. Am. Chem. Soc.*, 2008, **130**, 7532.
11. F. Wang, L. L. Feng, S. X. Dong, X. H. Liu and X. M. Feng, *Chem. Commun.*, 2020, **56**, 3233.


^{13}H , ^{13}C NMR spectra of the substrates and products



1J



1k









1s

7.470
7.451
7.352
7.333
7.314
7.275
7.257
7.245
- 6.335

~ 2.458
~ 2.178
~ 2.124
~ 1.914




2.00
2.04
1.03
1.00


9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0 -1.5

-162.720
-150.650
-142.467
/ 139.365
/ 135.662
/ 128.272
/ 127.332
- 125.954
- 116.515
- 111.799


- 64.454
~ 17.312
~ 12.197
~ 12.129
~ 7.569




(Z/E)-2-diazo-4-phenyl-1-(3,4,5-trimethyl-1H-pyrazol-1-yl)but-3-en-1-one




2a





d-2a




2b




2c




2d





2e




2f







2i





2j




2k









2m




2n







2p




2q




2r




L₂-Pi(OMe)₂




L₂-Pi(OEt)₂





L₂-Pi(O*i*Pr)₂




L₂-Pi(O*i*Bu)₂




L₂-Pi(Oipentyl)₂




L₂-Pi(OBn)₂




L₂-Pi(OPh)₂




3aa




3da





3ab






4ba








4ca




4da









4fa




4ga




4ha







4ia





4ja





4ka














40a







4qa




4ra




4sa




4ab




4ac




4ad




4ae




4af




4ag




4ah




4ai




4aj




4ak




4al








4am




4an












5aa




6aa




7aa




8aa







9da




2D NMR Spectra of **4aa**




COSY spectra of **4aa**



HSQC spectra of **4aa**



HMBC spectra of **4aa**



14 Copies of CD spectra in CH₂Cl₂

